

AUTHOR INDEX

VOLUME 15

- Adachi, Yoshikazu, 392
 Adriaens, P., 315
 Agbayani, M. M., 674
 Albers-Schönberg, George, 368
 Albert, Daniel M., 775
 Albritton, William L., 152, 294
 Allen, John G., 684
 An, F., 828
 Andrews, Gail P., 475
 Angehrn, Peter, 1
 Anné, J., 315
 Apelgren, Lynn D., 436
 Arakawa, Akira, 392
 Arbaczawski, Joseph, 608
 Astill, Mark, 204
 Aswapokee, Nalinee, 273, 444
 Aswapokee, Prasit, 273
 Atherton, Frank R., 677, 684, 696
 Audet, Pierre, 738
 Auperin, D., 134
 Auperin, David, 67
 Averett, Devron R., 428
- Baccanari, David P., 428
 Bach, Vinh T., 487
 Baker, Carol J., 544
 Baker, Edward E., 361
 Barry, A. L., 140
 Bartlett, Raymond C., 475, 769
 Barza, Michael, 50
 Bell, Stuart J., 384
 Bell, Susanne E., 554
 Bender, John F., 455
 Benedetto, Arrigo, 300
 Bergeron, Michel G., 635
 Bernfeld, Gerald E., 119
 Betts, Robert F., 269
 Beveridge, Terrance, J., 182, 820
 Bhamjee, A., 670
 Biddle, J. W., 243
 Bird, Thomas J., 93
 Birnbaum, Jerome, 361
 Black, Henry R., 165
 Blair, L. S., 372
 Blessing-Moore, Joann, 494
 Bloch, Richard, 46
 Bodey, Gerald P., 318, 447, 518
 Boggs, S., 716
 Bolduc, Cécile, 738
 Bosmans, Eugène, 535
 Boulton, Michael G., 332
 Bowen, William H., 440
 Boxall, Mike, 332
 Brammer, Keith W., 513, 831
 Brammer, K. W., 597
 Brass, Corstiaan, 763
- Brau, Carmen J., 807
 Breinig, Mary C., 547
 Bridgen, Pamela J., 420
 Briedis, Dalius J., 346
 Brier, Gordon L., 165
 Brodsky, Barbara, 651, 658
 Brook, Itzhak, 342
 Brorson, John-Erik, 572
 Brouillet, Mary D., 455
 Brown, Carol, 332
 Brown, M. R. W., 147
 Browne, Michael J., 747
 Brunton, James L., 294
 Bryan, L. E., 7
 Buckwold, Frederick J., 152
 Burchall, James J., 428
 Burg, Richard W., 361
 Butler, Thomas, 478
 Buxton, Alfred E., 608
- Cadge, B., 670
 Caloza, Dionisio L., Jr., 119
 Came, Paul E., 813
 Campbell, W. C., 372
 Carrizosa, Jaime, 200, 735
 Cassone, Antonio, 300
 Castaldo, Robert A., 81
 Chalet, Louis, 368
 Chan, Robert L., 258
 Cheadle, E. L., 484
 Chevli, Rekha, 258
 Christman, Judy L., 452
 Cifelli, S., 372
 Clay, Damonda L., 59
 Cleary, Paul P., 608, 616
 Clewell, D. B., 828
 Cline, Paul F., 547
 Cobbs, C. Glenn, 807
 Colaert, Jan, 535
 Cole, Douglas J., 368
 Cole, F. Sessions, 415
 Cole, Lucille J., 368
 Conrad, Robert S., 59
 Conterato, James P., 346
 Cooper, M. D., 484
 Coppens, L., 396
 Cox, D. A., 597
 Cozens, R. M., 147
 Crumpacker, Clyde S., 642
 Currie, Sara A., 361
 Curtis, Nigel A. C., 332
 Czerwinski, Anthony W., 161
- Dajani, Adnan S., 436
 D'Amato, Richard F., 229
 Damle, S. P., 828
- Daum, Robert S., 415
 DeArmon, Ira A., 420
 Deitch, Marc W., 55
 Delfini, Carlo, 300
 Delgado, Dennis G., 807
 DeStefano, Eugene, 723
 deWit, Sharon A., 494
 Dismukes, William E., 807
 Dornbusch, Kathrine, 263
 Douglas, R. Gordon, Jr., 269
 Dumon, L., 315
 Dymicky, M., 798
- Eary, C. H., 372
 Egerton, J. R., 372
 Eidson, Emerson E., 213
 Elion, Gertrude B., 554
 Emmerson, A. M., 497
 Eriksson, Bertil, 758
 Eriquez, Louis A., 229
 Evans, H. E., 674
 Eysen, H., 315
- Fancher, Marilyn J., 813
 Farmer, James L., 527
 Farrand, Stephen K., 93
 Feldman, William E., 240
 Field, Hugh J., 554
 Fillastre, J. P., 28
 Fitch, Coy D., 258
 Flickinger, M. C., 282
 Flor, James E., 368
 Fortner, Clarence L., 455
 Franco, Amalia, 478
 Friedman, Stanley A., 384
 Friedman-Kien, Alvin E., 723
 Fu, Kwung P., 171, 209, 273, 646, 834
- Gairola, Chandrachuranand, 42
 Ganguly, Rama, 269
 Gaspar, M. N., 470
 Gavan, Thomas L., 400
 Gearhart, Pam, 587
 Gerding, Dale N., 608, 616
 Gilbert, P., 147
 Gillett, A. P., 670
 Ginther, Charles L., 522
 Glass, L., 674
 Glew, Richard H., 87
 Glick, Melvin R., 491
 Glotzbecker, Cheryl, 836
 Goegelman, Robert T., 368
 Gold, Jerome A., 55
 Goldman, Donald A., 415
 Goldman, Peggy L., 802

AUTHOR INDEX

Goldner, Morris, 182, 820
 Gootz, Thomas D., 783
 Gorbach, Sherwood L., 50
 Goto, Norma, 628
 Greenberg, Richard N., 337
 Greenberg, Stephen B., 379
 Griebble, Hans G., 93, 50
 Gröschel, Dieter, 313
 Grose, William E., 447
 Gross, Gayle H., 220
 Guerrero, Isabel C., 712
 Gullo, Vincent P., 368
 Gump, Dieter W., 81
 Gymer, G. E., 597

Hall, Michael J., 677, 684, 696
 Hall, Wendell H., 562
 Hanson, Carl Veith, 461
 Hartman, Robert, 361
 Hassall, Cedric H., 677, 684, 696
 Hegarty, C. Paul, 55
 Hemmer, Robert J., 34
 Henderson, Earl E., 101
 Henriksen, Ruby, 152
 Henry, Matthew J., 603
 Holmes, Simon W., 684
 Hölte, Joachim-Volker, 177
 Hopfer, Roy L., 313
 Hughs, Rita A., 608
 Huhtanen, C. N., 798
 Humbert, Guy, 28
 Hurley, Laurence H., 42

Imada, Akira, 20
 Israel, Karen S., 165
 Iwata, Kazuo, 706

Jackson, George Gee, 540
 Jacobs, John Y., 580
 Jacobs, M. R., 470
 Jaffe, Harold W., 592
 Jasty, Venkatanarayana, 813
 Jernsek, Joseph G., 379
 Jevons, S., 597
 Jevons, Sidney, 513, 831
 Johnsson, Jan, 572
 Jones, D., 74
 Jones, William I., 420
 Joshua, Henry, 368
 Joyce, J. L., 351

Kamay, B., 408
 Kammer, R. B., 140
 Kandel, Judith S., 568
 Kaplan, Sheldon L., 544
 Karube, Isao, 126
 Kashiwazaki, Mamoru, 392
 Kaye, Donald, 200, 735
 Keeney, R. E., 484
 Kelly, Michael T., 754
 Kemawikasis, P., 674
 Kempf, August J., 368
 Khan, A. J., 674
 Kinnamon, Kenneth E., 157
 Kitai, Kazuhisa, 392
 Klustersky, J., 396

Klauber, M. R., 662
 Kleiman, Martin B., 491
 Klein, Frederick, 420
 Klein, Richard J., 723
 Klemperer, Ruth M., 147
 Kobasa, William D., 200, 735
 Kobayashi, G. S., 716
 Koch, Arthur L., 220
 Kong, Yu-Lin, 361
 Koornhof, H. J., 470
 Kotler-Brajtburg, J., 716
 Koup, Jeffrey R., 651, 658
 Kowand, S. K., 7
 Krellwitz, Wilson R., 368
 Krueger, G. G., 662
 Kudelski, Alicia, 738
 Kuhar, Michael J., 131
 Kuhrt, Michael F., 813
 Kumar, K., 674
 Kume, Tsuneo, 392

Lambert, Robert W., 677, 684, 696
 Landesman, Sheldon H., 50
 Landin, P., 134
 Lau, Alan H., 651, 658
 Lawrence, Paul J., 204
 LeBlanc, Barbara M., 318, 518
 Leeming, M. R. G., 597
 Leong, John, 384
 Lerner, Stephen A., 630
 Leroy, Annie, 28
 Lertzman, Joy, 152
 Levin, Myron J., 642
 Lewis, A. Carter, 337
 Lewiston, N. J., 494
 Lietman, Paul S., 131, 780
 Lipsky, James J., 780
 Liamont, M. J., 325
 Little, Wayne A., 440
 Livingstone, R., 670
 Lloyd, William J., 696
 Long, Walter K., 101, 131
 Loo, Ti Li, 447
 Love, Lillian J., 455
 Luft, Friedrich C., 46, 666
 Lyons, S. F., 484

MacCalman, J., 662
 Maccani, James E., 562
 MacGregor, Rob Roy, 712
 Maclean, Ian, 294
 Madsen, Paul O., 465
 Mahoney, David F., 14
 Mak, Linda L., 131
 Malow, James B., 540
 Martin, John E., Jr., 592
 Martin, R. Russell, 379
 Mason, Edward O., Jr., 544
 Maxwell, Douglas R., 46
 Maybury, Bonnie A., 494
 Mazens, Mary F., 475, 769
 McCammon, James R., 356
 McClean, Sandra L., 775
 McCormack, John J., 81
 McCracken, George H., Jr., 246,

ANTIMICROB. AGENTS CHEMOTHER.

481
 McGowan, John E., Jr., 137
 Medoff, G., 716
 Medoff, Gerald, 452
 Meheus, André, 535
 Meier, Anna M., 147
 Meingassner, J. G., 254
 Michel, Jacques, 580
 Miller, Brinton M., 361
 Miller, Thomas W., 368
 Mills, Karen, 313
 Moellering, Robert C., Jr., 87, 190
 Monaghan, Richard L., 361, 368
 Moore, Brian A., 513, 831
 Morahan, Page S., 547
 Morikawa, Yasushi, 126
 Murray, Barbara E., 190
 Murray, Byron K., 547
 Murray, Patrick R., 452
 Murray, P. R., 351

Nair, M. G., 730
 Nash, Anthony A., 554
 Nelson, John D., 481
 Neu, Harold C., 171, 209, 273, 444, 646, 834
 Nisbet, Louis J., 684
 Nord, Carl Erik, 263
 Norrby, Ragnar, 572
 Notkins, Abner L., 625
 Nozaki, Yukimasa, 20

Öberg, Bo, 758
 Obermeyer, Boyd D., 165
 Ochiai, Keiko, 126
 Oei, Tjien O., 491
 Ōiwa, Ruiko, 361
 Olexy, Vera M., 93
 Olson, George, 361
 Olsson, Barbro, 263
 Ōmura, Satoshi, 361
 Openshaw, Harry, 625
 Ormond, Robert E., 368
 Ostlind, D. A., 372
 Ott, John L., 14
 Overall, J. C., Jr., 662

Pahlavanzadeh, Hossein, 540
 Pancer, Francis, 813
 Pandey, R. C., 716
 Panwalker, Anand P., 540
 Park, No-Hee, 775
 Parsons, James N., 200
 Pavan-Langston, Deborah, 775
 Pederson, James A., 161
 Perlman, D., 282
 Perry, W., 74
 Petersdorf, Robert G., 802
 Peterson, Bryan C., 616
 Pettit, Diane, 628
 Pickering, Larry K., 587
 Piot, Peter, 535
 Putman, Margaret, 379
 Putter, Irving, 361, 368

Ramos, E., 142

- Rane, Dora S., 157
 Rankin, Laura I., 666
 Rankin, Laura L., 46
 Reinhardt, A., 134
 Renis, Harold E., 213
 Reuveni, Yaffa, 235
 Reynolds, Gladys H., 592
 Ribbecky, Renee, 101
 Ricketts, Robert T., 420
 Riek, R. G., 372
 Riesser, Valerie N., 356
 Rinehart, K. L., Jr., 716
 Ringrose, Peter S., 677, 684, 696
 Ritter, Dorothy A., 544
 Robins-Browne, R. M., 470
 Robson, Hugh G., 346
 Rodriguez, Nair, 465
 Ronald, Allan R., 152, 294
 Rosemond-Hornbeak, Hortencia, 730
 Rosenblatt, J. E., 351
 Rosenfield, W., 674
 Rosenthal, Leonard J., 235
 Roth, Barbara, 428
 Roy, Ira, 487
 Rudoj, Raul C., 628
 Rylander, Margareta, 572
- Sacks, Theodore, 580
 Sadowski, Peter L., 616
 Saito, Hajime, 504
 Salazar, D., 674
 Sample, Harry B., 491
 Sanders, Charles V., 337
 Sanders, Christine C., 783, 792
 Sanders, W. Eugene, Jr., 783, 792
 Sands, J. A., 134
 Sands, Jeffrey, 67, 134
 Scalcini, Marcella C., 337
 Schaeffer, S., 74
 Scheer, E. R., 408
 Schieri, Elizabeth A., 562
 Schimpff, S. C., 142
 Schimpff, Stephen C., 455
 Schlessinger, D., 716
 Schnipper, Lowell E., 642
 Schoenknecht, F. D., 140
 Schoenknecht, Fritz D., 400
 Schroeter, Arnold L., 592
 Schwartz, Jeffrey L., 123
 Schwartz, Surya P., 123
 Scudamore, R. Allan, 182, 820
 Semar, Richard W., 119
 Shadomy, S., 140
- Shah, Pramod P., 346
 Shainhouse, J. Zevi, 763
 Sherris, J. C., 140
 Shuster, C. W., 478
 Siegel, Jane D., 246
 Sirinavin, Sayomporn, 481
 Sirisanthana, Thira, 630
 Sisler, Hugh D., 603
 Slaughter, Richard L., 651, 658
 Slee, A. M., 408
 Sloan, Rebecca S., 46
 Smith, Arnold L., 415
 Smith, Craig R., 780
 Smith, James W., 491
 Snipes, Wallace, 67
 Snyderman, David R., R., 50
 Sonnenwirth, A. C., 351
 Spruance, S. L., 662
 Spyker, Daniel A., 28
 Stamm, Walter E., 608
 Stapley, Edward O., 361
 Steck, Edgar A., 157
 Stern, Timothy A., 568
 Stevens, David A., 763
 Stringfellow, D. A., 111
 Suhayda, D., 372
 Suzuki, Shuichi, 126
 Swain, Richard R., 666
- Tally, Francis P., 50
 Tanzer, J. M., 408
 Teller, Lynn, 415
 Temple, Matthew J., 420
 Terry, Pamela M., 137
 Thadepalli, Haragopal, 487
 Thayer, James D., 592
 Then, Rudolf L., 1
 Thomas, Marion L., 246
 Thomson, Lynn A., 440
 Thornhill, D. P., 670
 Thornberry, C., 140, 470
 Thornberry, Clyde, 243, 400
 Threlkeld, Norma, 246
 Thurner, J., 254
 Timmons, R. F., 142
 Tomich, P. K., 828
 Tomioka, Haruaki, 504
 Trottier, Sylvie, 635
 Tunac, Josefino B., 361
 Turner, J. R., 14
- Uemura, Herbert, 628
 Underwood, G. E., 111
 Urui, Jean-Paul, 535
- Van Den Elzen, H. M., 7
 Van Der Linden, M. P., 325
 van Dyck, Eddy, 535
 Vaudaux, Pierre, 34
 Vézina, Claude, 738
- Wachsmuth, I. K., 470
 Waldman, Robert H., 269
 Waldvogel, Francis A., 34
 Walker, Barry R., 55
 Wallace, Richard J., Jr., 379
 Wallick, Hyman, 361
 Ward, J. I., 470
 Washington, J. A., 140
 Washington, John A., II., 400
 Watanabe, Takashi, 504
 Watanakunakron, Chatrchai, 836
 Waterworth, Pamela M., 497
 Weaver, Susanne S., 318, 518
 Webb, David, 487
 Weed, S. D., 111
 Welch, David F., 754
 Welling, Peter G., 465
 Welling, P. G., 670
 White, G. Wesley, 540
 White, John S., 204
 Wiernik, Peter H., 455
 Wildy, Peter, 554
 Wilson, Kenneth E., 368
 Wilson, Samuel Z., 379
 Wise, R., 670
 Wohlenberg, Charles, 625
 Wolen, Robert L., 165
 Wolny, James D., 165
 Wulf, R. Gary, 59
- Yamaguchi, Hideyo, 706
 Yeager, Anne S., 494
 Yoneda, Masahiko, 20
 Young, Viola Mae, 455
 Yourassowsky, E., 325
 Yu, Pauline K. W., 400
 Yum, Moo Nahm, 46
- Zaia, John A., 642
 Zaidi, Akbar A., 592
 Ziege, Edgar A., 165
 Zimelis, Victoria M., 540
 Zoon, Kathryn C., 420
 Zweighaft, Teresa, 240

SUBJECT INDEX

VOLUME 15

- Aciclovir
 - herpes simplex encephalitis, 775
 - mice, 775
- Acinetobacter calcoaceticus* subsp. *anitratum* (*Herellea vaginicola*)
 - aminoglycoside-modifying enzymes, 190
 - aminoglycoside resistance, 190
- Actinomycin D
 - African green monkey kidney cell lines, 300
 - drug uptake, 300
 - transcription inhibition, 300
- Acycloguanosine
 - aciclovir in mice, 775
 - experimental herpes simplex encephalitis, 775
 - growth inhibition, 642
 - herpesviruses, humans, 642
 - latent herpes simplex virus, 723
- Acycloguanosine treatment
 - acute herpes simplex infections, 554
 - latent herpes simplex infections, 554
 - mice, 554
- Adenine arabinoside
 - antidiuretic hormone, 142
- Aerobic bacilli
 - carbenicillin resistance, 137
- African green monkey kidney cell lines
 - actinomycin D, 300
 - 37 RC cells, drug uptake, 300
- African trypanosomes
 - antitumor drugs, 157
- Agar dilution-replicator yeast susceptibility test
 - variability, 763
- Agar dilution susceptibility
 - correlation with disk diffusion susceptibility, 834
- Agar minimum inhibitory concentration
 - cefamandole, cefoxitin, and cefuroxime, 572
- D-Alanine carboxypeptidase
 - B. subtilis* cells, 204
 - cephapirin, 204
- Alaphosphin
 - phosphonopeptide, 684
- Alcohols
 - enveloped viruses, sensitivity, 67
- Alpha hemolysin
 - viridin B (streptococcal bacteriocin), 436
- Amikacin
 - disk diffusion susceptibility test, 400
 - interaction between gentamicin, tobramycin, or netilmicin and carbenicillin or ticarcillin, 567
- Aminoglycoside antibiotic resistance
 - anaerobic bacteria, 7
 - B. fragilis*, 7
 - C. perfringens*, 7
- Aminoglycoside-induced nephrotoxicity
 - relationship with auditory toxicity, 780
- Aminoglycoside-modifying enzymes
 - A. calcoaceticus* subsp. *anitratum* (*Herellea vaginicola*), 190
- Aminoglycoside resistance
 - A. calcoaceticus* subsp. *anitratum* (*H. vaginicola*), 190
- Aminoglycosides
 - azlocillin, ampicillin, mezlocillin, piperacillin, ticarcillin, alone and in combination, 540
- Amoxicillin
 - dosage nomogram, 28
 - impaired renal function, 28
 - intravenously, 628
 - pediatric patients, 628
- Amphotericin B
 - microdilution and broth dilution techniques, 475
- Ampicillin
 - aminoglycosides, 540
 - clavulanic acid, 315
 - Haemophilus* species, 836
 - H. influenzae*, 325
 - H. influenzae* type B, 415
 - N. meningitidis*, 240
 - P. aeruginosa*, 93
 - S. marcescens*, 93
 - S. pneumoniae*, 240
- Ampicillin-aminoglycoside combinations
 - group B streptococci, 484
 - synergism, 484
- Ampicillin level
 - human blood, 510
 - interstitial fluid, 510
- Ampicillin resistance
 - H. ducreyi*, 294
 - plasmid-mediated, 294
- Anaerobic bacteria
 - low trimethoprim susceptibility, 1
- Anaerobic susceptibility
 - various methods, 351
- Anthelmintic agents
 - avermectins, 361, 368, 372
 - B₁₂ component, 372
 - chromatographic properties, 368
 - fermentation, 361
 - isolation, 368
 - producing organism, 361
- Antibacterial agents
 - alaphosphin, 684, 696
 - phosphonopeptides, 677, 684, 696
- Antibiotic assay
 - blood specimen collection, 481
- Antibiotic degradation
 - pneumococci, 470
- Antibiotic resistance
 - effects of carbon sources, 59
 - P. aeruginosa*, 59
- Antibiotic strains

- N. gonorrhoeae*, 535
- Antidiuretic hormone
adenine arabinoside, 142
- Antifolate activity
HeLa cells, 730
isoaminopterin, 730
- Antifolate resistance
B. subtilis *thyA*, 527
- Antimicrobial susceptibility test
tetrazolium reduction, 769
- Antineoplastic antibiotics
S. aureus, 580
- Antiplateau agents
cationic detergents, 408
- Anti-pseudomonas activity
azlocillin, 396
mezlocillin, 396
ticarcillin, 396
- Antiviral agent
arildone, 813
- Antiviral agents
latent herpes simplex virus, 625
- Arildone
antiviral agent, 813
- Aspiration pneumonia
children, 342
clindamycin, 342
- Auditory toxicity
relationship with aminoglycoside nephrotoxicity, 780
- Avermectins
anthelmintic agents, 361, 368, 372
B₁₂ component, 372
chromatographic properties, 368
fermentation, 361
isolation, 368
producing organism, 361
- Azacytidine (5-Azacytidine)
BSC-1 cells, 235
cytoplasmic ribosomal RNA, 235
messenger RNA, 235
- Azlocillin
aminoglycosides, 540
anti-pseudomonas activity, 396
- Bacampicillin level
human blood, 510
interstitial fluid, 510
- Bacillus licheniformis*
bacitracin production, 282
- Bacitracin
B. licheniformis, 282
oxygen-enriched aeration, 282
- Bacitracin production
polyacrylamide gel, 126
- Bactec radiometric method
yeast susceptibility, 313
- Bacteriocin
M. smegmatis, 504
purification, properties, cytotoxic effect, 504
- Bacteroides fragilis*
aminoglycoside antibiotic resistance, 7
 β -lactam antibiotics, 263
- Bay K 4999
broad-spectrum penicillin, 670
furazlocillin, 783
- Benzylpenicillin
clavulanic acid, 315
- Beta-lactam antibiotic
thienamycin, 518
- Beta-lactam antibiotics
B. fragilis, 263
clavulanic acid, 315
compared with furazlocillin, piperacillin, and mezlocillin, 783
E. coli K-12, 182
outer-membrane penetration barriers, 182
- Beta-lactamases
cefamandole, 792
cefoxitin-inducible, 792
- BHK-21 cells
mumps virus, 356
ribavirin, 356
- Bilirubin
chloramphenicol, 544
colorimetric assay, 544
- Blood specimen collection
antibiotic assay, 481
- BL-5786 (ceforanide)
parenteral cephalosporin, 318
- Bronchopulmonary infections
Haemophilus spp., 807
- Broth dilution techniques
amphotericin B, 475
5-fluorocytosine, 475
susceptibility testing, 475
- Broth minimum inhibitory concentration
cefamandole, cefoxitin, and cefuroxime, 572
- BSC-1 cells
5-azacytidine, 235
- B. subtilis* *thyA*
antifolate resistance, 527
- B₁₂* component
anthelmintic agents, 372
avermectins, 372
- Candida* species
2,4-diaminoquinazoline compounds, 93
- Carbenicillin
clavulanic acid, 315
gentamicin nephrotoxicity, 46
interaction between gentamicin, tobramycin, netilmicin, or amikacin and ticarcillin, 587
P. aeruginosa, 93
S. marcescens, 93
- Cationic detergents
antiplateau agents, 408
- Cefaclor
cephalosporins, 836
Haemophilus species, 836
- Cefamandole
agar MIC, 572
anaerobic infections, 337
bronchopulmonary infections, 807
broth MIC, 572
cefoxitin-inducible beta-lactamases, 792
disk diffusion susceptibility test, 140
Haemophilus species, 836
Haemophilus spp. bronchopulmonary infections, 807
H. influenzae, 325
inflammatory exudate, 712

SUBJECT INDEX

- newborn infants, 674
- penetration, 712
- pharmacokinetics, 674
- renal impairment, 161
- resistance, 792
- S. aureus* abscesses, 200
- Cefatrizine activity
 - cephalosporins, 209
- Cefazafur
 - in vitro activity, 444
 - β -lactamase stability, 444
- Cefazolin
 - S. aureus* abscesses, 200
 - serious infections, 119
- Ceforanide
 - BL-5786, 318
 - parenteral cephalosporin, 318
- Cefoxitin
 - agar MIC, 572
 - broth MIC, 572
 - S. aureus* abscesses, 200
- Cefuroxime
 - agar MIC, 572
 - broth MIC, 572
- Cephalosporin
 - BL-5786 (ceforanide), 318
 - HR 756, 452
 - N. gonorrhoeae*, 452
 - SCE-129, 646
- Cephalosporins
 - cefatrizine activity, 209
 - dissociated resistance, 497
 - Haemophilus* species, 836
 - in vitro activity, 444
 - β -lactamase stability, 444
- Cephalothin
 - clavulanic acid, 315
 - creatinine clearance concentration, 666
 - disk diffusion susceptibility, 140
 - gentamicin nephrotoxicity, 46
 - inflammatory exudate, 712
 - S. aureus* abscesses, 200
 - S. aureus* endocarditis, 735
- Cephalothin level
 - human blood, 510
 - interstitial fluid, 510
- Cepharmycin C
 - S. lactamdurans*, 522
 - sporulation and production, 522
- Cephapirin
 - D-alanine carboxypeptidase formation, 204
 - B. subtilis* cells, 204
- Cephapirin level
 - human blood, 510
 - interstitial fluid, 510
- Cephatricle
 - inflammatory exudate, 712
- Cephradine
 - serious infections, 119
- Chloramphenicol
 - bilirubin, 544
 - biological fluids, 491
 - colorimetric assay, 544
 - Haemophilus* species, 836
 - high-pressure liquid chromatographic assay, 491
 - H. influenzae* type B, 415

ANTIMICROB. AGENTS CHEMOTHER.

- hospitalized patients, 651
- N. meningitidis*, 240
- pharmacokinetics, 651
- serum and saliva concentrations, 658
- S. pneumoniae*, 240
- Chloroquine resistance
 - malaria, 258
 - mefloquine, 258
- Chlorpromazine
 - DNA viruses, 461
 - photochemical inactivation, 461
 - RNA viruses, 461
- Cinoxacin
 - humans, 165
 - influence of probenecid, 465
 - serum levels, 465
 - urinary excretion, 465
- Clavulanic acid
 - ampicillin, 315
 - benzylpenicillin, 315
 - carbenicillin, 315
 - carbenicillin and gentamicin, in vitro synergism, 630
 - cephalothin, 315
 - S. marcescens*, 630
- Clindamycin
 - aspiration pneumonia, 342
 - children, 342
 - β -lactamase-negative and -positive *N. gonorrhoeae*, 143
- Clostridium botulinum*
 - p-hydroxybenzoic acid n-alkyl esters, 798
- Clostridium perfringens*
 - aminoglycoside antibiotic resistance, 7
- Colorimetric Assay
 - bilirubin, 544
 - chloramphenicol, 544
- Creatinine clearance
 - cephalothin, 666
 - concentration, 666
- Cystic fibrosis patients
 - Pseudomonas*, 494
- Cytoplasmic ribosomal ribonucleic acid
 - 5-azacytidine, 235
- Deoxyribonucleic acid viruses
 - chlorpromazine, 461
 - photochemical inactivation, 461
- 2,4-Diaminoquinazoline
 - Candida* sp., 93
- 1,5-Diamino anthraquinones
 - antiviral properties, 111
 - interferon-inducing properties, 111
- N,N*-dihexadecyl-m-xylylenediamine
 - interferon inducer, 269
 - rhinovirus challenge, 269
- Dihydrofolate reductase
 - Neisseria* sp., 428
- Dihydrofolate reductases
 - low trimethoprim susceptibility, 1
- 5,6-Dihydro-5-azathymidine
 - herpes simplex virus infections, 213
- Disk diffusion susceptibility test
 - amikacin, 400
- Disk diffusion susceptibility tests

- cefamandole and cephalothin, 140
- Dodecylimidazole
sterol biosynthesis, 603
U. maydis, 603
- Enterobacteriaceae*
cefamandole, susceptibility to, 14
cefoxitin, susceptibility to, 14
 β -lactamase production, 14
piperacillin and other antibiotics, 346
spontaneous mutants, 14
- Enterococci
penicillin combined with gentamicin, 87
protein binding, 87
- Enveloped viruses
herpes simplex, 67
long-chain unsaturated monoglycerides and alcohols, 67
- Enveloped virus inactivation
fatty acid derivatives, 134
- Epstein-Barr virus expression
human umbilical cord leukocytes, 74
- Erythromycin
 β -lactamase-negative and -positive *N. gonorrhoeae*, 243
nasal cultures, 379
oral therapy, 379
S. aureus carriers, 379
- Escherichia coli*
cephalosporins, 513
inhibition of transpeptidase activity, 831
penicillin-binding proteins, 20
penicillins, 513
peptidoglycan transpeptidase inhibition, 513
resistant strains, 177
SCE-963, 20
streptomycin uptake, 177
thienamycin, 831
- Escherichia coli* K-12
 β -lactam antibiotics, 182
 β -lactam antibiotics, 332
outer-membrane penetration barriers, 182
penicillin-binding proteins, 332
- Experimental herpes simplex encephalitis
aciclovir, 775
acycloguanosine, 775
mice, 775
- Experimental staphylococcal endocarditis
methicillin tolerance, 802
- Fatty acid derivatives
enveloped virus inactivation, 134
- Fatty acyl group
imidazole antimycotics, 706
lecithin liposomes, 706
- Fluorocytosine (5-Fluorocytosine)
amphotericin B, 475
microdilution and broth dilution techniques, 475
- 5-Fluorocytosine
yeast susceptibility, 313
- Furazlocillin
Bay K 4999, 783
compared with mezlocillin, piperacillin, and β -lactam antibiotics, 783
- Gentamicin
cortical distribution, 635
interaction between tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin, 587
medullary distribution, 635
methicillin, 34
P. aeruginosa, 93
papillary distribution, 635
single or multiple doses, 635
S. marcescens, 93
- Gentamicin nephrotoxicity
carbenicillin, 46
cephalothin, 46
- [³H]Gentamicin
autoradiographic localization, 131
proximal renal tubules, 131
- Gonococcal urethritis
penicillin cure, 592
- Gram-negative aerobic bacilli
piperacillin, susceptibility, 137
ticarcillin, susceptibility, 137
- Gram-negative bacterial infection
netilmicin, 50
- Group B streptococci
ampicillin-aminoglycoside combinations, 484
- Haemophilus ducreyi*
ampicillin resistance, 294
- Haemophilus influenzae*
ampicillin, 325
 β -lactamase negative, 325
 β -lactamase positive, 325
cefamandole, 325
- Haemophilus influenzae* type B
ampicillin, 415
chloramphenicol, 415
- Haemophilus spec.*
ampicillin, 836
cefactor, 836
cefamandole, 836
chloramphenicol, 836
tetracycline, 836
- Haemophilus* spp.
bronchopulmonary infections, 807
- HeLa cells
antifolate activity, 730
isoaminopterin, 730
- Herpes simplex infections
acycloguanosine, 554
mice, 554
- Herpes simplex virus
long-chain unsaturated monoglycerides and alcohols, 67
- Herpes simplex virus infections
5,6-dihydro-5-azathymidine, 213
pyran, 547
- Herpesviruses
acycloguanosine, 642
human infections, 642
- Herpesvirus mutants
phosphonoacetate, 758
phosphonoformate, 758
- High-pressure liquid chromatographic assay
chloramphenicol, 491
- HR 756
cephalosporin, 273, 452
gram-negative aerobic and anaerobic bacteria, 273

SUBJECT INDEX

ANTIMICROB. AGENTS CHEMOTHER.

- gram-positive aerobic and anaerobic bacteria, 273
- N. gonorrhoeae*, 452
- Human lymphoid interferon
 - concentration, 420
 - large-scale production, 420
- Human umbilical cord leukocytes
 - Epstein-Barr virus-induced transformation, 101
- p*-Hydroxybenzoic acid *n*-alkyl esters
 - C. botulinum*, 798
- Imidazole antimycotics, 706
 - lecithin liposomes, 706
- Imidazole derivative
 - ticlozazole (UK-20,349), 597
- Impaired renal function
 - amoxicillin, 28
- Inflammatory exudate
 - cephalosporins, 712
- Interferon inducer
 - N,N*-dihexadecyl-*m*-xylenediamine, 269
- Isoaminopterin
 - antifolate activity, 730
 - HeLa cells, 730
- Josamycin
 - β -lactamase-negative and -positive *N. gonorrhoeae*, 243
- Killer phenomenon
 - pathogenic yeast, 568
- Kitasamycin (leucomycin)
 - biosynthesis, 738
 - S. kitasatoensis*, 738
- Klebsiella pneumoniae*
 - nosocomial, 616
 - nosocomial multiply resistant, 608
 - R plasmids, 616
- β -Lactam antibiotics
 - antibacterial activity, 332
- β -Lactamase
 - affinity chromatography, 229
 - N. gonorrhoeae*, 229
- β -Lactamase production
 - Non-*Streptomyces Actinomycetales*, 123
- β -Lactamases
 - inhibition, 171
- β -lactamase stability
 - cefazafur, 444
 - cephalosporins, 444
 - SCE-129, 646
- Latent herpes simplex virus
 - acycloguanosine, 723
 - antiviral agents, 625
 - hairless mice, 723
 - reactivation, 625
 - sensory ganglia, 723
- Lecithin liposomes
 - fatty acyl group, 706
 - imidazole antimycotics, 706
 - sterol composition, 706
- Leucomycin (kitasamycin)
 - biosynthesis, 738
 - S. kitasatoensis*, 738
- Leukemic patients
 - microbial suppression, 455
 - vancomycin, 455
- Levamisole
 - recurrent herpes simplex labialis, 662
- Malaria
 - chloroquine resistance, 258
 - mefloquine, 258
- Mefloquine
 - malaria, 258
- Messenger ribonucleic acid
 - 5-azacytidine, 235
 - BSC-1 cells, 235
- Methicillin
 - gentamicin, 34
 - S. aureus*, 34
 - S. aureus* endocarditis, 735
- Methicillin tolerance
 - experimental staphylococcal endocarditis, 802
- N*-
 - methylothioformohydroxamate metal complexes
 - antibiotic action, 384
- Metronidazole
 - T. vaginalis*, 254
- Mezlocillin
 - aerobic and anaerobic bacteria, 487
 - aminoglycosides, 540
 - anti-pseudomonas activity, 396
 - compared with furazocillin, piperacillin, and beta-lactam antibiotics, 783
- Mice
 - [³H]gentamicin autoradiographic localization, 131
- Miconazole
 - sterol biosynthesis, 603
 - U. maydis*, 603
- Microdilution techniques
 - amphotericin B, 475
 - 5-fluorocytosine, 475
 - susceptibility testing, 475
- Monoglycerides
 - enveloped virus, sensitivity, 67
- Mumps virus
 - BHK-21 cells, 356
 - ribavirin, 356
- Mycobacterium fortuitum* complex
 - antimicrobial susceptibility testing, 754
- Mycobacterium smegmatis*
 - bacteriocin, 504
- Nafcillin
 - S. aureus* endocarditis, 735
- Neisseria gonorrhoeae*
 - HR 756, 452
 - β -lactamase, 229
 - penetrability of the outer membrane, 820
 - penicillin, 820
 - penicillinase-negative, 562
 - penicillinase-positive, 562
 - rosamicin, josamycin, erythromycin, and clindamycin, 243
 - susceptibility to 30 antibiotics, 562
- Neisseria gonorrhoeae* strains
 - antibiotic susceptibility, 535
 - Europe and Africa, 535
- Neisseria meningitidis*

- ampicillin, 240
- Neisseria* sp.
 - dihydrofolate reductase, 428
- Netilmicin
 - cortical distribution, 635
 - gram-negative bacterial infections, 50
 - interaction between gentamicin, tobramycin, or amikacin and carbenicillin or ticarcillin, 587
 - medullary distribution, 635
 - newborn infants, 246
 - papillary distribution, 635
 - single or multiple doses, 635
- Netilmicin disk diffusion susceptibility
 - correlation with agar dilution susceptibility, 834
- Newborn infants
 - cefamandole, 674
 - netilmicin, 246
- N. meningitidis*
 - chloramphenicol, 240
- Non-*Streptomyces* Actinomycetales
 - β -lactamase production, 123
- Novel β -lactam compounds
 - inhibition, 171
 - β -lactamases, 171
- Nucleoside analogs
 - Epstein-Barr virus expression, 101
 - Epstein-Barr virus-induced transformation, 101
- Oral ampicillin
 - double-blind clinical trials, 55
- Oral cyclocillin
 - double-blind clinical trials, 55
- pAD1
 - S. faecalis* subsp. *zymogenes* strain DS16, 828
- pAD2
 - S. faecalis* subsp. *zymogenes* strain DS16, 828
- P. aeruginosa*
 - piperacillin and other antibiotics, 346
- P. aeruginosa* NCTC 6750
 - spheroplasts, 147
- Pathogenic yeast
 - killer phenomenon, 568
- Penicillin
 - Bay k 4999, 670
 - gonococcal urethritis, 592
 - N. gonorrhoeae*, 820
 - other antibiotics, 820
- Penicillin-binding proteins
 - E. coli* K-12, 332
 - β -lactam antibiotics, 332
 - SCE-963, 20
- Penicillins
 - cephalosporins, 513
 - combined with gentamicin, 87
 - enterococci, 87
 - peptidoglycan transpeptidase inhibition, 513
 - protein binding, 87
- Peptidoglycan transpeptidase inhibition
 - cephalosporins, 513
 - E. coli*, 513
 - P. aeruginosa*, 513
 - penicillins, 513
- Phosphonoacetate
 - herpesvirus mutants, 758
- Phosphonoformate
 - herpesvirus mutants, 758
- Phosphonopeptides
 - alaphosphin, 696
 - antibacterial agents, 677, 684, 696
 - chemistry, 677
 - rationale, 677
 - structure-activity relationships, 677
- Piperacillin
 - aminoglycosides, 540
 - ampicillin, compared with, 346
 - carbenicillin, compared with, 346
 - cefamandole, compared with, 346
 - cephalothin, compared with, 346
 - compared with furazlocillin, piperacillin, and beta-lactam antibiotics, 783
 - Enterobacteriaceae*, 346
 - gram-negative aerobic bacilli, 137
 - P. aeruginosa*, 346
 - ticarcillin, compared with, 346
- Pneumococci
 - antibiotic degradation, 470
 - resistance mechanisms, 470
- Polyacrylamide gel
 - bacitracin production, 126
- Polyene antibiotics
 - mouse erythrocytes, 716
 - potassium leakage, 716
 - S. cerevisiae* hemolysis, 716
 - S. cerevisiae* lethality, 716
- Polymyxin B
 - P. aeruginosa* NCTC 6750, 147
 - spheroplasts, 147
- Probenecid
 - serum levels of cinoxacin, 465
 - urinary excretion of cinoxacin, 465
- Protein binding
 - penicillins combined with gentamicin, 87
- Proximal renal tubules
 - [³H]gentamicin, 131
 - mice, 131
- Pseudomonas*
 - cystic fibrosis patients, 494
 - rough, smooth, and mucoid colony types, 494
- Pseudomonas aeruginosa*
 - antibiotic resistance, 59
 - cephalosporins, 513
 - penicillins, 513
 - peptidoglycan transpeptidase inhibition, 513
 - S. marcescens* transferring antibiotic resistance, 93
- Pseudomonas aeruginosa* NCTC 6750
 - polymyxin B, 147
 - suspending media, 147
- Pyran
 - effect on latency, 547
 - herpes simplex virus infections, 547
- Pyrrolo(1,4)benzodiazepine
 - tryptophan conversion, 42
- 37 RC cells
 - actinomycin D, 300
- Recurrent herpes simplex labialis
 - levamisole, 662
- Renal impairment
 - cefamandole, 161
- Rhinovirus

- N,N*-dihexadecyl-*m*-xylenediamine, 269
humans, 269
- Ribavirin
BHK-21 cells, 356
mechanism and specificity of action, 747
mumps virus, 356
- Ribonucleic acid viruses
chlorpromazine, 461
photochemical inactivation, 461
- Rifampin susceptibility
growth conditions, 220
- Rosamicin
 β -lactamase-negative and -positive *N. gonorrhoeae*, 243
nasal cultures, 379
oral therapy, 379
S. aureus carriers, 379
- R plasmids
nosocomial *Klebsiella pneumoniae* infections, 616
- Saccharomyces cerevisiae*
polyene antibiotics, 716
- Salmonella group H1 factor
response to antimicrobial therapy, 478
virulence, 478
- SCE-129
antibacterial activity, 646
 β -lactamase stability, 646
- SCE-963
cephalosporin, 20
E. coli, 20
- Serine protease
S. lactamdurans, 522
sporulation and production, 522
- Serratia marcescens*
carbenicillin and gentamicin, in vitro synergism, 630
clavulanic acid, 630
transfer of ampicillin, carbenicillin, and gentamicin resistance, 93
- Sibromycin
anthranilic acid moieties, 42
- S. pneumoniae*
chloramphenicol, 240
- Staphylococcus aureus*
antineoplastic antibiotics, 580
cefazolin, cephalothin, cefoxitin, and cefamandole, 200
gentamicin, 34
gentamicin resistance, 152
methicillin-resistant, 34
- Staphylococcus aureus* carriers
erythromycin, 379
nasal cultures, 379
placebo, 379
rosamicin, 379
- Staphylococcus aureus* endocarditis
cephalothin, 735
methicillin, 735
nafcillin, 735
- Staphylococcus aureus* phage type 92
methicillin-resistant strains, 74
- Sterol biosynthesis
dodecylimidazole, 603
miconazole, 603
- Streptococcal bacteriocin (viridin B)
alpha hemolysin, 428
Streptococcus faecalis subsp. *zymogenes* strain DS16
multiple drug resistance, 828
pAD1, 828
pAD2, 828
plasmid-related transmissibility, 828
Streptococcus mutans
antibiotic susceptibility, 440
serotype profiles, 440
Streptococcus pneumoniae
ampicillin, 240
Streptomyces kitasatoensis
kitasamycin, 738
leucine analog-resistant mutants, 738
Streptomyces lactamdurans
cephamycin C, 522
serine protease, 522
Streptomycin uptake
E. coli, 177
- Tetracycline
Haemophilus species, 836
- Tetrazolium reduction
antimicrobial susceptibility test, 769
- Thienamycin
beta-lactam antibiotic, 518
broad-spectrum activity, 518
transpeptidase activity in *E. coli*, 831
- Ticarcillin
aminoglycosides, 540
anti-pseudomonas activity, 396
gram-negative aerobic bacilli, 137
interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin, 587
- Tioconazole (UK-20,349)
antifungal activity, 597
imidazole derivative, 597
- Tobramycin
interaction between gentamicin, netilmicin, or amikacin and carbenicillin or ticarcillin, 587
- Tomamycin
anthranilic acid moieties, 42
- Transpeptidase activity
inhibition in *E. coli*, 831
thienamycin, 831
- Treponema hyodysenteriae*
39 antimicrobial agents, 392
- Trichomonas vaginalis*
metronidazole, 254
5-nitroimidazoles, 254
- Trimethoprim-sulfamethoxazole
intravenously administered, 447
- Trimethoprim susceptibility
anaerobic bacteria, 1
dihydrofolate reductases, 1
- Tryptophan
sibromycin, 42
tomamycin, 42
- Tryptophan conversion
pyrrolo(1,4)benzodiazepine, 42
- Ustilago maydis*
dodecylimidazole, 603
miconazole, 603
sterol biosynthesis, 603

ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 15

WASHINGTON, DC 20006

1979

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 15 • 1979

EDITORIAL BOARD

GLADYS L. HOBBY, *Editor-in-Chief* (1980)
Infectious Disease Research Institute, Livingston, N.J.
WALTER D. CELMER, *Editor* (1980)
Pfizer Inc., Groton, Conn.
HERBERT L. ENNIS, *Editor* (1982)
*Roche Institute of Molecular Biology,
Nutley, N.J.*

JOEL G. FLAKS, *Editor* (1981)
University of Pennsylvania, Philadelphia
EDWARD W. HOOK, *Editor* (1981)
University of Virginia, Charlottesville
LEON H. SCHMIDT, *Editor* (1979)
Southern Research Institute, Birmingham, Ala.

Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1980)
Robert Austrian (1980)
Arthur L. Barry (1980)
John Bennett (1981)
Lawrence E. Bryan (1979)
D. Buyske (1980)
Yves Chabbert (1980)
Royston C. Clowes (1979)
C. Glenn Cobbs (1980)
Paul S. Cohen (1980)
Naomi Datta (1981)
Julian Davies (1979)
Lawrence E. Day (1980)
R. Gordon Douglas, Jr. (1980)
Theodore Eickhoff (1979)
Arthur English (1980)
David S. Feingold (1981)
Robert Fekety (1981)
Robert J. Fitzgerald (1980)
Anthony J. Glazko (1981)
Irving H. Goldberg (1979)
Harry Gooder (1979)
Jack Gwaltney (1980)
Fred Hahn (1979)
Robert L. Hamill (1979)
Maurice W. Harmon (1981)
Michael Higgins (1980)
Ronald D. Hinsdill (1979)
Richard Hornick (1980)

L. H. Huang (1979)
Milton Huppert (1980)
George Gee Jackson (1980)
Thomas Jones (1980)
William J. Jusko (1980)
Donald Kaye (1979)
Jerome O. Klein (1979)
Vernon Knight (1980)
George S. Kobayashi (1979)
Jordan Konisky (1980)
Matthew E. Levison (1981)
Friedrich C. Luft (1981)
Joan Lusk (1980)
R. Luthy (1980)
Gerald L. Mandell (1980)
Gerald Medoff (1980)
L. Bruce Mellett (1979)
S. Mitsunashi (1980)
Robert C. Moellering, Jr. (1979)
R. B. Morin (1979)
Bernard Moss (1981)
John D. Nelson (1980)
Harold C. Neu (1980)
J. F. Niblack (1980)
T. J. Perun (1980)
Charles A. Plate (1979)
Burton M. Pogell (1981)
K. E. Price (1979)
Paul Quie (1980)
W. H. G. Richards (1980)
Mark H. Richmond (1979)

R. W. Rickards (1980)
Richard Roberts (1979)
Richard Root (1980)
Jon E. Rosenblatt (1979)
Milton R. J. Salton (1981)
Merle Sande (1979)
Jay Sanford (1980)
Arthur K. Saz (1979)
F. C. Sciavolino (1979)
Oldrich K. Sebek (1980)
William M. Shannon (1980)
John C. Sherris (1979)
Charles Shipman, Jr. (1979)
Robert W. Sidwell (1981)
Walter Siegenthaler (1980)
Sigmund S. Socransky (1980)
P. Frederick Sparling (1981)
R. Sutherland (1979)
Vera L. Sutter (1981)
Morton N. Swartz (1979)
Clyde Thornsberry (1979)
Ralph Tompsett (1979)
Hamao Umezawa (1981)
Donald Van Harken (1979)
D. Vazquez (1980)
Michael Waring (1981)
John Washington II (1981)
Jerry A. Weisbach (1979)
B. Weisblum (1979)
Peter G. Welling (1979)
Richard Wenzel (1980)

Robert A. Day, *Managing Editor*
Gisella Pollock, *Assistant Managing Editor*
Lorraine Gilbert, *Production Editor*
1913 I St., NW, Washington, DC 20006

EX OFFICIO

Edwin H. Lennette, *President* (1978-1979)
J. Mehseu Joseph, *Secretary*

Willis A. Wood, *President-Elect* (1978-1979)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., N.W., Washington, D.C. 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents and chemotherapy, including cancer chemotherapy. Instructions to Authors are published in the January issue each year. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is \$65 per year. The member subscription price is \$16 per year. Single copies are \$6. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

Second class postage paid at Washington, D.C. 20006, and at additional mailing offices.

Made in the United States of America.

Copyright © 1979, American Society for Microbiology.

All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

- Low Trimethoprim Susceptibility of Anaerobic Bacteria Due to Insensitive Dihydrofolate Reductases. RUDOLF L. THEN* AND PETER ANGEHRN 1
- Mechanism of Aminoglycoside Antibiotic Resistance in Anaerobic Bacteria: *Clostridium perfringens* and *Bacteroides fragilis*. L. E. BRYAN,* S. K. KOWAND, AND H. M. VAN DEN ELZEN 7
- SCE-963, a New Potent Cephalosporin with High Affinity for Penicillin-Binding Proteins 1 and 3 of *Escherichia coli*. YUKIMASA NOZAKI,* AKIRA IMADA, AND MASAHITO YONEDA 20
- Pyrrolo(1,4)benzodiazepine Antitumor Antibiotics: Biosynthetic Studies on the Conversion of Tryptophan to the Anthranilic Acid Moieties of Sibiromycin and Tomaymycin. LAURENCE H. HURLEY* AND CHANDRACHURANAND GAIROLA 42
- Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols. JEFFREY SANDS,* DAVID AUVERIN, AND WALLACE SNIPES 67
- Production of β -Lactamase by Non-*Streptomyces Actinomycetales*. JEFFREY L. SCHWARTZ* AND SURYA P. SCHWARTZ 123
- Bacitracin Production by Whole Cells Immobilized in Polyacrylamide Gel. YASUSHI MORIKAWA, KEIKO OCHIAI, ISAO KARUBE,* AND SHUCHI SUZUKI 126
- Enveloped Virus Inactivation by Fatty Acid Derivatives. J. A. SANDS,* P. LANDIN, D. AUVERIN, AND A. REINHARDT 134

Physiological Effects and Microbial Susceptibility

- Lack of Correlation Between β -Lactamase Production and Susceptibility to Cefamandole or Cefoxitin Among Spontaneous Mutants of *Enterobacteriaceae*. JOHN L. OTT,* J. R. TURNER, AND DAVID F. MAHONEY 14
- Methicillin Potentiates the Effect of Gentamicin on Methicillin-Resistant *Staphylococcus aureus*. ROBERT J. P. HEMMER, PIERRE VAUDAUX, AND FRANCIS A. WALDVOGEL* 34
- Effects of Carbon Sources on Antibiotic Resistance in *Pseudomonas aeruginosa*. ROBERT S. CONRAD,* R. GARY WULF, AND DAMONDA L. CLAY 59
- Methicillin-Resistant Strains of *Staphylococcus aureus* Phage Type 92. S. SCHAEFLER,* W. PERRY, AND D. JONES 74
- Activity of 2,4-Diaminoquinazoline Compounds Against *Candida* Species. ROBERT A. CASTALDO, DIETER W. GUMP,* AND JOHN J. MCCORMACK 81
- Hospital Isolates of *Serratia marcescens* Transferring Ampicillin, Carbenicillin, and Gentamicin Resistance to Other Gram-Negative Bacteria Including *Pseudomonas aeruginosa*. VERA M. OLEXY, THOMAS J. BIRD, HANS G. GRIEBLE, AND STEPHEN K. FARRAND* 93
- Effects of Nucleoside Analogs on Epstein-Barr Virus-Induced Transformation of Human Umbilical Cord Leukocytes and Epstein-Barr Virus Expression in Transformed Cells. EARL E. HENDERSON,* WALTER K. LONG, AND RENEE RIBECKY 101
- Susceptibility of Gram-Negative Aerobic Bacilli Resistant to Carbenicillin in a General Hospital to Piperacillin and Ticarcillin. JOHN E. MCGOWAN, JR.,* AND PAMELA M. TERRY 137
- Interpretive Criteria for Cefamandole and Cephalothin Disk Diffusion Susceptibility Tests. A. L. BARRY,* F. D. SCHOENKNECHT, S. SHADOMY, J. C. SHERRIS, C. THORNSBERRY, J. A. WASHINGTON, AND R. B. KAMMER 140

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

Pharmacology and Therapeutics

Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function. GUY HUMBERT, DANIEL A. SPYKER,* J. P. FILLASTRE, AND ANNIE LEROY	28
Protection from Gentamicin Nephrotoxicity by Cephalothin and Carbenicillin. RICHARD BLOCH,* FRIEDRICH C. LUFT, LAURA I. RANKIN, REBECCA S. SLOAN, MOO NAHM YUM, AND DOUGLAS R. MAXWELL	46
Netilmicin in Serious Gram-Negative Bacterial Infections. DAVID R. SNYDMAN,* FRANCIS P. TALLY, SHELDON H. LANDESMAN, MICHAEL BARZA, AND SHERWOOD L. GORBACH	50
Double-Blind Clinical Trials of Oral Cyclacillin and Ampicillin. JEROME A. GOLD,* C. PAUL HEGARTY, MARC W. DEITCH, AND BARRY R. WALKER	55
Effect of Protein Binding on the Activity of Penicillins in Combination with Gentamicin Against Enterococci. RICHARD H. GLEW* AND ROBERT C. MOELLERING, JR.	87
Antiviral and Interferon-Inducing Properties of 1,5-Diamino Anthraquinones. D. A. STRINGFELLOW,* S. D. WEED, AND G. E. UNDERWOOD	111
Intravenous Use of Cephadrine and Cefazolin Against Serious Infections. DIONISIO L. CALOZA, JR.,* RICHARD W. SEMAR, AND GERALD E. BERNFELD	119
Autoradiographic Localization of [³ H]Gentamicin in the Proximal Renal Tubules of Mice. MICHAEL J. KU HAR, LINDA L. MAK, AND PAUL S. LIETMAN*	131
Inappropriate Antidiuretic Hormone Following Adenine Arabinoside Administration. E. RAMOS,* R. F. TIMMONS, AND S. C. SCHIMPF	142

Errata

Antimicrobial Susceptibility and Selection of Resistance Among <i>Staphylococcus epidermidis</i> Isolates Recovered from Patients with Infections of Indwelling Foreign Devices. GORDON L. ARCHER	145
Prediction of Cefazolin Penetration into High- and Low-Protein-Containing Extravascular Fluid: New Method for Performing Simultaneous Studies. LANCE R. PETERSON AND DALE N. GERDING	145

Volume 15 Contents for February Number 2

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Induction of Streptomycin Uptake in Resistant Strains of <i>Escherichia coli</i> . JOACHIM-VOLKER HÖLTJE	177
Outer-Membrane Penetration Barriers as Components of Intrinsic Resistance to Beta-Lactam and Other Antibiotics in <i>Escherichia coli</i> K-12. R. ALLEN SCUDAMORE,* TERRANCE J. BEVERIDGE, AND MORRIS GOLDNER	182
Aminoglycoside-Modifying Enzymes Among Clinical Isolates of <i>Acinetobacter calcoaceticus</i> subsp. <i>anitratus</i> (<i>Herellae vaginicola</i>): Explanation for High-Level Aminoglycoside Resistance. BARBARA E. MURRAY* AND ROBERT C. MOELLERING, JR.	190
Growth Conditions and Rifampin Susceptibility. ARTHUR L. KOCH* AND GAYLE H. GROSS	220
Purification by Affinity Chromatography and Properties of a β -Lactamase Isolated from <i>Neisseria gonorrhoeae</i> . LOUIS A. ERIQUEZ* AND RICHARD F. D'AMATO	229
Effect of 5-Azacytidine on Cytoplasmic Ribosomal and Messenger Ribonucleic Acids in BSC-1 Cells. YAFFA REUVENI AND LEONARD J. ROSENTHAL*	235

Chloroquine Resistance in Malaria: Accessibility of Drug Receptors to Mefloquine. COY D. FITCH,* ROBERT L. CHAN, AND REKHA CHEVLI	258
Factors Contributing to Resistance to Beta-Lactam Antibiotics in <i>Bacteroides fragilis</i> . BARBRO OLSSON, KATHRINE DORNBUSCH, AND CARL ERIK NORD*	263
Application of Oxygen-Enriched Aeration in the Production of Bacitracin by <i>Bacillus licheniformis</i> . M. C. FLICKINGER* AND D. PERLMAN	282
Plasmid-Mediated Ampicillin Resistance in <i>Haemophilus ducreyi</i> . JAMES L. BRUNTON, IAN MACLEAN, ALLAN R. RONALD, AND WILLIAM L. ALBRITTON*	294
Resistance of African Green Monkey Kidney Cell Lines to Actinomycin D: Drug Uptake in 37 RC Cells After Persistent Inhibition of Transcription. ARRIGO BENEDETTO,* ANTONIO CASSONE, AND CARLO DELFINI	300

Physiological Effects and Microbial Susceptibility

Influence of Suspending Media upon the Susceptibility of <i>Pseudomonas aeruginosa</i> NCTC 6750 and Its Spheroplasts to Polymyxin B. RUTH M. KLEMPERER,* P. GILBERT, ANNA M. MEIER, R. M. COZENS, AND M. R. W. BROWN	147
Comparative Inhibition of β -Lactamases by Novel β -Lactam Compounds. KWUNG P. FU AND HAROLD C. NEU*	171
Effect of Cephapirin on Formation of D-Alanine Carboxypeptidase in Growing <i>Bacillus subtilis</i> Cells. JOHN S. WHITE,* MARK ASTILL, AND PAUL J. LAWRENCE	204
Cefatrizine Activity Compared with That of Other Cephalosporins. HAROLD C. NEU* AND KWUNG P. FU	209
Effect of Ampicillin and Chloramphenicol Against <i>Streptococcus pneumoniae</i> and <i>Neisseria meningitidis</i> . WILLIAM E. FELDMAN* AND TERESA ZWEIGHAFT	240
In Vitro Activity of Rosamicin, Josamycin, Erythromycin, and Clindamycin Against β -Lactamase-Negative and β -Lactamase-Positive Strains of <i>Neisseria gonorrhoeae</i> . J. W. BIDDLE* AND CLYDE THORNSBERRY	243
HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria. HAROLD C. NEU,* NALINEE ASWAPOKEE, PRASIT ASWAPOKEE, AND KWUNG P. FU	273
Radiometric Method for Determining the Susceptibility of Yeasts of 5-Fluorocytosine. ROY L. HOPFER,* KAREN MILLS, AND DIETER GRÖSCHEL	313
Effect of Clavulanic Acid on the Minimum Inhibitory Concentration of Benzylpenicillin, Ampicillin, Carbenicillin, or Cephalothin Against Clinical Isolates Resistant to Beta-Lactam Antibiotics. L. DUMON, P. ADRIAENS, J. ANNÉ, AND H. EYSSEN*	315
BL-S786 (eforanide), a New Parenteral Cephalosporin: In Vitro Studies. SUSANNE S. WEAVER, BARBARA M. LEBLANC, AND GERALD P. BODEY*	318

Pharmacology and Therapeutics

Investigations of the Occurrence of Gentamicin-Resistant <i>Staphylococcus aureus</i> . FREDERICK J. BUCKWOLD, WILLIAM L. ALBRITTON, ALLEN R. RONALD, JOY LERTZMAN, AND RUBY HENRIKSEN	152
Activity of Antitumor Drugs Against African Trypanosomes. KENNETH E. KINAMON,* EDGAR A. STECK, AND DORA S. RANE	157
Pharmacokinetics of Cefamandole in Patients with Renal Impairment. ANTHONY W. CZERWINSKI* AND JAMES A. PEDERSON	161
Pharmacology of Cinoxacin in Humans. HENRY R. BLACK,* KAREN S. ISRAEL, ROBERT L. WOLEN, GORDON L. BRIER, BOYD D. OBERMEYER, EDGAR A. ZIEGE, AND JAMES D. WOLNY	165

Treatment of Experimental <i>Staphylococcus aureus</i> Abscesses: Comparison of Cefazolin, Cephalothin, Cefoxitin, and Cefamandole. DONALD KAYE,* JAMES N. PARSONS, JAIME CARRIZOSA, AND WILLIAM D. KOBASA	200
Activities of 5,6-Dihydro-5-Azathymidine Against Herpes Simplex Virus Infections in Mice. HAROLD E. RENIS* AND EMERSON E. EIDSON	213
Pharmacokinetic Properties of Netilmicin in Newborn Infants. JANE D. SIEGEL, GEORGE H. MCCRAKEN, JR.,* MARION L. THOMAS, AND NORMA THRELKELD	246
Strain of <i>Trichomonas vaginalis</i> Resistant to Metronidazole and Other 5-Nitroimidazoles. JOSEF G. MEINGASSNER* AND JOSEPHINE THURNER	254
Lack of Effect of an Interferon Inducer, <i>N,N</i> -Dihexadecyl- <i>m</i> -Xylenediamine, on Rhinovirus Challenge in Humans. R. GORDON DOUGLAS, JR.,* ROBERT H. WALDMAN, ROBERT F. BETTS, AND RAMA GANGULY	256
<i>Errata</i>	
Improved Susceptibility Disk Assay Method Employing an Agar Overlay Technique. BLONDELL ANDERSON	323
Penetration of Methicillin, Oxacillin, and Cephalothin into Bone and Synovial Tissues. ROBERT H. FITZGERALD, JR., PATRICK J. KELLY, ROBERT J. SNYDER, AND JOHN A. WASHINGTON II	323

Volume 15

Contents for March

Number 3

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Inhibition of <i>Escherichia coli</i> K-12 by β -Lactam Antibiotics with Poor Antibacterial Activity: Interaction of Permeability and Intrinsic Activity Against Penicillin-Binding Proteins. NIGEL A. C. CURTIS,* CAROL BROWN, MIKE BOXALL, AND MICHAEL G. BOULTON	332
Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation. RICHARD W. BURG,* BRINTON M. MILLER, EDWARD E. BAKER, JEROME BIRNBAUM, SARA A. CURRIE, ROBERT HARTMAN, YU-LIN KONG, RICHARD L. MONAGHAN, GEORGE OLSON, IRVING PUTTER, JOSEFINO B. TUNAC, HYMAN WALLICK, EDWARD O. STAPLEY, RUIKO ÔIWA, AND SATOSHI ÔMURA	361
Avermectins, New Family of Potent Anthelmintic Agents: Isolation and Chromatographic Properties. THOMAS W. MILLER,* LOUIS CHAIET, DOUGLAS J. COLE, LUCILLE J. COLE, JAMES E. FLOR, ROBERT T. GOEGELMAN, VINCENT P. GULLO, HENRY JOSHUA, AUGUST J. KEMPF, WILSON R. KRELLWITZ, RICHARD L. MONAGHAN, ROBERT E. ORMOND, KENNETH E. WILSON, GEORGE ALBERS-SCHÖNBERG, AND IRVING PUTTER	368
Antibiotic Action of <i>N</i> -Methylthioformohydroxamate Metal Complexes. STUART J. BELL, STANLEY A. FRIEDMAN, AND JOHN LEONG*	384
Large-Scale Production and Concentration of Human Lymphoid Interferon. FREDERICK KLEIN,* ROBERT T. RICKETTS, WILLIAM I. JONES, IRA A. DEARMON, MATTHEW J. TEMPLE, KATHRYN C. ZOON, AND PAMELA J. BRIDGEN	420
Purification of Streptococcal Bacteriocin (Viridin B) and Its Separation from Alpha Hemolysin. LYNN D. APELGREN AND ADNAN S. DAJANI*	436
Photochemical Inactivation of Deoxyribonucleic and Ribonucleic Acid Viruses by Chlorpromazine. CARL VEITH HANSON	461
Resistance Mechanisms of Mutiply Resistant Pneumococci: Antibiotic Degradation Studies. R. M. ROBINS-BROWN,* M. N. GASPAR, J. I. WARD, I. K. WACHSMUTH, H. J. KOORNHOF, M. R. JACOBS, AND C. THORNSBERRY	470

Physiological Effects and Microbial Susceptibility

Growth Curves, Microscopic Morphology, and Subcultures of Beta-Lactamase-Positive and -Negative <i>Haemophilus influenzae</i> Under the Influence of Ampicillin and Cefamandole. E. YOURASSOWSKY,* M. P. VAN DER LINDEN, AND M. J. LISMONT	325
In Vitro Activity of Piperacillin Compared with That of Carbencillin, Ticarcillin, Ampicillin, Cephalothin, and Cefamandole Against <i>Pseudomonas aeruginosa</i> and <i>Enterobacteriaceae</i> . PRAMOD P. SHAH, DALIUS J. BRIEDIS, HUGH G. ROBSON,* AND JAMES P. CONTERATO	346
Comparison of Anaerobic Susceptibility Results Obtained by Different Methods. J. E. ROSENBLATT,* P. R. MURRAY, A. C. SONNENWIRTH, AND J. L. JOYCE	351
Effects of Ribavirin on BHK-21 Cells Acutely or Persistently Infected with Mumps Virus. JAMES R. MCCAMMON* AND VALERIE W. RIESSER	356
In Vitro Activity of 39 Antimicrobial Agents Against <i>Treponema hyodysenteriae</i> . KAZUHISA KITAI,* MAMORU KASHIWAZAKI, YOSHIKAZU ADACHI, TSUNEO KUME, AND AKIRA ARAKAWA	392
Comparative Study of Anti- <i>Pseudomonas</i> Activity of Azlocillin, Mezlocillin, and Ticarcillin. L. COPPENS* AND J. KLASTERSKY	396
Interpretation of the Disk Diffusion Susceptibility Test for Amikacin: Report of a Collaborative Study. JOHN A. WASHINGTON II, PAULINE K. W. YU, THOMAS L. GAVAN, FRITZ D. SCHOENKNECHT, AND CLYDE THORNSBERRY	400
In Vitro Evaluation of Seven Cationic Detergents as Antiplatelet Agents. J. M. TANZER,* A. M. SLEE, B. KAMAY, AND E. R. SCHEER	408
Effect of Ampicillin and Chloramphenicol Alone and in Combination on Ampicillin-Susceptible and -Resistant <i>Haemophilus influenzae</i> Type B. F. SESSIONS COLE,* ROBERT S. DAUM, LYNN TELLER, DONALD A. GOLDMANN, AND ARNOLD L. SMITH	415
Dihydrofolate Reductase from <i>Neisseria</i> sp. DEVRON R. AVERETT,* BARBARA ROTH, JAMES J. BURCHALL, AND DAVID P. BACCANARI	428
Antibiotic Susceptibility of <i>Streptococcus mutans</i> : Comparison of Serotype Profiles. WAYNE A. LITTLE,* LYNN A. THOMSON, AND WILLIAM H. BOWEN ...	440
In Vitro Activity and β -Lactamase Stability of Cefazafur Compared with Those of β -Lactamase-Stable Cephalosporins. NALINEE ASWAPOKEE AND HAROLD C. NEU*	444
In Vitro Activity of HR 756, a New Cephalosporin Against <i>Neisseria gonorrhoeae</i> . PATRICK R. MURRAY,* JUDY L. CHRISTMAN, AND GERALD MEDOFF	452
Comparison of Microdilution and Broth Dilution Techniques for the Susceptibility Testing of Yeasts to 5-Fluorocytosine and Amphotericin B. MARY F. MAZENS,* GAIL P. ANDREWS, AND RAYMOND C. BARTLETT	475
Synergistic Effects of Ampicillin-Aminoglycoside Combinations on Group B Streptococci. M. D. COOPER,* R. E. KEENEY, S. F. LYONS, AND E. L. CHEATLE ...	484
In Vitro Activity of Mezlocillin and Its Related Compounds Against Aerobic and Anaerobic Bacteria. HARAGOPAL THADEPALLI,* IRA ROY, VINH T. BACH, AND DAVID WEBB	487
Antimicrobial Susceptibilities of Rough, Smooth, and Mucoid Colony Types of <i>Pseudomonas</i> Isolated from Cystic Fibrosis Patients. BONNIE A. MAYBURY,* JOANN BLESSING-MOORE, SHARON A. DEWIT, N. J. LEWISTON, AND ANNE S. YEAGER	494

Pharmacology and Therapeutics

Cefamandole Therapy in Anaerobic Infections. RICHARD N. GREENBERG,* MARCELLA C. SCALCINI, CHARLES V. SANDERS, AND A. CARTER LEWIS	337
---	-----

Clindamycin in Treatment of Aspiration Pneumonia in Children. ITZHAK BROOK	342
Avermectins, New Family of Potent Anthelmintic Agents: Efficacy of the B _{1a} Component. J. R. EGERTON,* D. A. OSTLIND, L. S. BLAIR, C. H. EARY, D. SUHAYDA, S. CIFELLI, R. F. RIEK, AND W. C. CAMPBELL	372
Quantitative Nasal Cultures from Carriers of <i>Staphylococcus aureus</i> : Effects of Oral Therapy with Erythromycin, Rosamicin, and Placebo. SAMUEL Z. WILSON,* R. RUSSELL MARTIN, MARGARET PUTMAN, STEPHEN B. GREENBERG, RICHARD J. WALLACE, JR., AND JOSEPH G. JEMSEK	379
Clinical Pharmacology of Intravenously Administered Trimethoprim-Sulfamethoxazole. WILLIAM E. GROSE, GERALD P. BODEY,* AND TI LI LOO	447
Role of Vancomycin as a Component of Oral Nonabsorbable Antibiotics for Microbial Suppression in Leukemic Patients. JOHN F. BENDER,* STEPHEN C. SCHIMPF, VIOLA MAE YOUNG, CLARENCE L. FORTNER, MARY D. BROUILLET, LILLIAN J. LOVE, AND PETER H. WIERNIK	455
Influence of Probenecid on Serum Levels and Urinary Excretion of Cinoxacin. NAIR RODRIGUEZ, PAUL O. MADSEN, AND PETER G. WELLING*	465
Effect of a <i>Salmonella</i> Group H1 R Factor on Virulence and Response of Infections to Antimicrobial Therapy. THOMAS BUTLER,* C. W. SHUSTER, AND AMALIA FRANCO	478
Pitfalls in Collecting Blood Specimens for Antibiotic Assay. SAYOMPORN SIRINAVIN, JOHN D. NELSON,* AND GEORGE H. MCCracken, JR.	481
High-Pressure Liquid Chromatographic Assay of Chloramphenicol in Biological Fluids. R. H. BARRY SAMPLE,* MELVIN R. GLICK, MARTIN B. KLEIMAN, JAMES W. SMITH, AND TJEN O. OEI	491
<i>Erratum</i>	
Comparison of the In Vitro Activities of HR756 with Cephalothin, Cefoxitin, and Cefamandole. JACOB P. SOSNA, PATRICK R. MURRAY, AND GERALD MEDOFF	497

Volume 15

Contents for April

Number 4

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Dissociated Resistance Among Cephalosporins. PAMELA M. WATERWORTH* AND A. M. EMMERSON	497
Purification, Properties, and Cytotoxic Effect of a Bacteriocin from <i>Mycobacterium smegmatis</i> . HAJIME SAITO,* TAKASHI WATANABE, AND HARUAKI TOMIOKA	504
Peptidoglycan Transpeptidase Inhibition in <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> by Penicillins and Cephalosporins. BRIAN A. MOORE,* SIDNEY JEVONS, AND KEITH W. BRAMMER	513
Sporulation and the Production of Serine Protease and Cephameycin C by <i>Streptomyces lactamdurans</i> . CHARLES L. GINTHER	522
Effect of Time and Concentration Upon Interaction Between Gentamicin, Tobramycin, Netilmicin, or Amikacin and Carbenicillin or Ticarcillin. LARRY K. PICKERING* AND PAM GEARHART	592
Effects of Miconazole and Dodecylimidazole on Sterol Biosynthesis in <i>Ustilago maydis</i> . MATTHEW J. HENRY* AND HUGH D. SISLER	603
Physical Characterization of Ten R Plasmids Obtained from an Outbreak of Nosocomial <i>Klebsiella pneumoniae</i> Infections. PETER L. SADOWSKI, BRYAN C. PETERSON, DALE N. GERDING,* AND PAUL P. CLEARY	616

Physiological Effects and Microbial Susceptibility

Thienamycin: New Beta-Lactam Antibiotic With Potent Broad-Spectrum Activity. SUSANNE S. WEAVER, GERALD P. BODEY,* AND BARBARA M. LEBLANC	518
--	-----

CONTENTS

ix

Conditional Antifolate Resistance in <i>Bacillus subtilis</i> thyA. JAMES L. FARMER .	527
Antibiotic Susceptibility of <i>Neisseria gonorrhoeae</i> Strains from Europe and Africa. PETER PIOT,* EDDY VAN DYCK, JAN COLAERT, JEAN-PAUL URSI, EUGÈNE BOSMANS, AND ANDRÉ MEHEUS .	535
Comparative In Vitro Activity of Azlocillin, Ampicillin, Mezlocillin, Piperacillin, and Ticarcillin, Alone and in Combination with an Aminoglycoside. G. WESLEY WHITE,* JAMES B. MALOW, VICTORIA M. ZIMELIS, HOSSEIN PAHLAVAN-ZADEH, ANAND P. PANWALKER, AND GEORGE GEE JACKSON .	540
Comparative Susceptibility of Penicillinase-Positive and -Negative <i>Neisseria gonorrhoeae</i> to 30 Antibiotics. WENDELL H. HALL,* ELIZABETH A. SCHIERL, AND JAMES E. MACCANI .	562
Killer Phenomenon in Pathogenic Yeast. JUDITH S. KANDEL AND TIMOTHY A. STERN* .	568
Comparison Between Agar and Broth Minimum Inhibitory Concentrations of Cefamandole, Cefoxitin, and Cefuroxime. MARGARETA RYLANDER,* JOHN-ERIK BRORSON, JAN JOHNSON, AND RAGNAR NORREY .	572
Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against <i>Staphylococcus aureus</i> . JOHN Y. JACOBS,* JACQUES MICHEL, AND THEODORE SACKS .	580
Nosocomial Mutiply Resistant <i>Klebsiella pneumoniae</i> : Epidemiology of an Outbreak of Apparent Index Case Origin. DALE N. GERDING,* ALFRED E. BUXTON, RITA A. HUGHES, PAUL P. CLEARY, JOSEPH ARBACZAWSKI, AND WALTER E. STAMM .	608
In Vitro System for Studying the Efficacy of Antiviral Agents in Preventing the Reactivation of Latent Herpes Simplex Virus. CHARLES WOHLNBERG, HARRY OPENSHAW, AND ABNER L. NOTKINS* .	625
Effect of Clavulanic Acid on the In Vitro Synergism Between Carbenicillin and Gentamicin Against <i>Serratia marcescens</i> . THIRA SIRISANTHANA AND STEPHEN A. LERNER* .	630

Pharmacology and Therapeutics

Bacampicillin, Ampicillin, Cephalothin, and Cephapirin Levels in Human Blood and Interstitial Fluid. JAMES S. TAN* AND SARA-JANE SALSTROM .	510
Modification of the Colorimetric Assay for Chloramphenicol in the Presence of Bilirubin. EDWARD O. MASON, JR.,* SHELDON L. KAPLAN, CAROL J. BAKER, AND DOROTHY A. RITTER .	544
Effect of Pyran on Latency After Herpes Simplex Virus Infections. PAGE S. MORAHAN,* PAUL F. CLINE, MARY C. BREINIG, AND BYRON K. MURRAY .	547
Effect of Acycloguanosine Treatment on Acute and Latent Herpes Simplex Infections in Mice. HUGH J. FIELD,* SUSANNE E. BELL, GERTRUDE B. ELION, ANTHONY A. NASH, AND PETER WILDY .	554
Pharmacokinetic Determinants of Penicillin Cure of Gonococcal Urethritis. HAROLD W. JAFFE, ARNOLD L. SCHROETER, GLADYS H. REYNOLDS,* AKBAR A. ZAIDI, JOHN E. MARTIN, JR., AND JAMES D. THAYER .	587
Antifungal Activity of Tioconazole (UK-20,349), a New Imidazole Derivative. S. JEVONS,* G. E. GYMER, K. W. BRAMMER, D. A. COX, AND M. R. G. LEEMING .	597
Pharmacokinetics of Intravenous Amoxicillin in Pediatric Patients. RAUL C. RUDOY,* NORMA GOTO, DIANE PETTIT, AND HERBERT UEMURA .	628

Erratum

Effect of Treatment with 5-Ethyl-2'-Deoxyuridine on Herpes Simplex Virus Encephalitis in Normal and Immunosuppressed Mice. WILLIAM B. DAVIS, JOHN E. OAKES, AND JOHN A. TAYLOR .	633
--	-----

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

- Phosphonopeptides as Antibacterial Agents: Rationale, Chemistry, and Structure-Activity Relationships. FRANK R. ATHERTON, MICHAEL J. HALL, CEDRIC H. HASSALL,* ROBERT W. LAMBERT, AND PETER S. RINGROSE 677
- Phosphonopeptides as Antibacterial Agents: Mechanism of Action of Alaphosphin. FRANK R. ATHERTON, MICHAEL J. HALL, CEDRIC H. HASSALL,* ROBERT W. LAMBERT, WILLIAM J. LLOYD, AND PETER S. RINGROSE 696
- Classification of Polyene Antibiotics According to Chemical Structure and Biological Effects. J. KOTLER-BRAJTURG, G. MEDOFF, G. S. KOBAYASHI,* S. BOGGS, D. SCHLESSINGER, R. C. PANDEY, AND K. L. RINEHART, JR. 716
- Antifolate Activity of Isoaminopterin in HeLa Cells. HORTENCIA ROSEMOND-HORNBEAK* AND M. G. NAIR 730
- Biosynthesis of KITASAMYCIN (Leucomycin) by Leucine Analog-Resistant Mutants of *Streptomyces kitasatoensis*. CLAUDE VÉZINA,* CÉCILE BOLDUC, ALICIA KUDELSKI, AND PIERRE AUDET 738

Physiological Effects and Microbial Susceptibility

- In Vitro Antibacterial Activity and β -Lactamase Stability of SCE-129, a New Cephalosporin. HAROLD C. NEU* AND KWUNG P. FU 646
- Effect of Fatty Acyl Group and Sterol Composition on Sensitivity of Lecithin Liposomes to Imidazole Antimycotics. HIDEYO YAMAGUCHI* AND KAZUO IWATA 706

Pharmacology and Therapeutics

- Influence of Single or Multiple Doses of Gentamicin and Netilmicin on Their Cortical, Medullary, and Papillary Distribution. MICHEL G. BERGERON* AND SYLVIE TROTTIER 635
- Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections. CLYDE S. CRUMPACKER,* LOWELL E. SCHNIPPER, JOHN A. ZAIA, AND MYRON J. LEVIN 642
- Chloramphenicol Pharmacokinetics in Hospitalized Patients. JEFFREY R. KOUP,* ALAN H. LAU, BARBARA BRODSKY, AND RICHARD L. SLAUGHTER 651
- Relationship Between Serum and Saliva Chloramphenicol Concentrations. JEFFREY R. KOUP,* ALAN H. LAU, BARBARA BRODSKY, AND RICHARD L. SLAUGHTER 658
- Treatment of Recurrent Herpes Simplex Labialis with Levamisole. S. L. SPRUANCE,* G. G. KRUEGER, J. MACCALMAN, J. C. OVERALL, JR., AND M. R. KLAUBER 662
- Effect of Cephalothin on Measurement of Creatinine Concentration. LAURA I. RANKIN,* RICHARD R. SWAIN, AND FRIEDRICH C. LUFT 666
- Pharmacokinetics of Bay k 4999, a New Broad-Spectrum Penicillin. R. WISE,* B. CADGE, A. P. GILLET, A. BHAMJEE, R. LIVINGSTONE, P. G. WELLING, AND D. P. THORNHILL 670
- Pharmacokinetics and Safety of Cefamandole in Newborn Infants. M. M. AGBAYANI,* A. J. KHAN, P. KEMAWIKASIT, W. ROSENFELD, D. SALAZAR, K. KUMAR, L. GLASS, AND H. E. EVANS 674
- Phosphonopeptides as Antibacterial Agents: Alaphosphin and Related Phosphonodipeptides. JOHN G. ALLEN, FRANK R. ATHERTON, MICHAEL J. HALL, CEDRIC H. HASSALL,* SIMON W. HOLMES, ROBERT W. LAMBERT, LOUIS J. NISBET, AND PETER S. RINGROSE 684

Comparative Penetration of Various Cephalosporins into Inflammatory Exudate. ISABEL C. GUERRERO AND ROB ROY MACGREGOR*	712
Latent Herpes Simplex Virus Infections in Sensory Ganglia of Hairless Mice Prevented by Acycloguanosine. RICHARD J. KLEIN,* ALVIN E. FRIEDMAN- KIEN, AND EUGENE DESTEFANO	723
Effectiveness of Nafcillin, Methicillin, and Cephalothin in Experimental <i>Staphylo-</i> <i>coccus aureus</i> Endocarditis. JAIME CARRIZOSA, WILLIAM D. KOBASA, AND DONALD KAYE*	735

Volume 15

Contents for June

Number 6

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Mechanism and Specificity of Action of Ribavirin. MICHAEL J. BROWNE	747
Characteristics of Herpesvirus Mutants Resistant to Phosphonoformate and Phos- phonoacetate. BERTIL ERIKSSON* AND BO ÖBERG	758
Emergence of Resistance to Cefamandole: Possible Role of Cefoxitin-Inducible Beta-Lactamases. CHRISTINE C. SANDERS* AND W. EUGENE SANDERS, JR.	792
Inhibition of <i>Clostridium botulinum</i> by <i>p</i> -Hydroxybenzoic Acid <i>n</i> -Alkyl Esters. M. DYMICKY* AND C. N. HUHTANEN	798
Preliminary Studies of the Mode of Action of Arildone, a Novel Antiviral Agent. MICHAEL F. KUERT,* MARILYN J. FANCHER, VENKATANARAYANA JASTY, FRANCIS PANCIC, AND PAUL E. CAME	813
Penetrability of the Outer Membrane of <i>Neisseria gonorrhoeae</i> in Relation to Acquired Resistance to Penicillin and Other Antibiotics. R. ALLAN SCUDA- MORE,* TERRANCE J. BEVERIDGE, AND MORRIS GOLDNER	820
Plasmid-Related Transmissibility and Multiple Drug Resistance in <i>Streptococcus</i> <i>faecalis</i> subsp. <i>Zymogenes</i> Strain DS16. P. K. TOMICH, F. AN, S. P. DAMLE, AND D. B. CLEWELL*	828

Physiological Effects and Microbial Susceptibility

Antimicrobial Susceptibility Testing of <i>Mycobacterium fortuitum</i> Complex. DAVID F. WELCH AND MICHAEL T. KELLY*	754
Variability of Agar Dilution-Replicator Method of Yeast Susceptibility Testing. CORSTIAAN BRASS,* J. ZEVI SHAINHOUSE, AND DAVID A. STEVENS	763
Rapid Antimicrobial Susceptibility Test Using Tetrazolium Reduction. RAYMOND C. BARTLETT* AND MARY F. MAZENS	769
In Vitro Activity of Furazlocillin (Bay k 4999) Compared with Those of Mezlocillin, Piperacillin, and Standard Beta-Lactam Antibiotics. THOMAS D. GOOTZ,* CHRISTINE C. SANDERS, AND W. EUGENE SANDERS, JR.	783
Inhibition of Transpeptidase Activity in <i>Escherichia coli</i> by Thienamycin. BRIAN A. MOORE,* SIDNEY JEVONS, AND KEITH W. BRAMMER	831
Correlation of Netilmicin Disk Diffusion Susceptibility and Agar Dilution Suscep- tibility. KWUNG P. FU AND HAROLD C. NEU*	834
Comparative Susceptibility of <i>Haemophilus</i> Species to Cefaclor, Cefamandole, and Five Other Cephalosporins and Ampicillin, Chloramphenicol, and Tetracycline. CHATRCHAI WATANAKUNAKORN* AND CHERYL GLOTZBECKER	836

Pharmacology and Therapeutics

Therapy of Experimental Herpes Simplex Encephalitis with Aciclovir in Mice. NO- HEE PARK, DEBORAH PAVAN-LANGSTON,* SANDRA L. MCCLEAN, AND DANIEL M. ALBERT	775
--	-----

Relationship Between Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity. CRAIG R. SMITH,* JAMES J. LIPSKY, AND PAUL S. LIETMAN	780
Significance of Methicillin Tolerance in Experimental Staphylococcal Endocarditis. PEGGY L. GOLDMAN AND ROBERT G. PETERSDORF*	802
Clinical and Laboratory Evaluation of Cefamandole in the Therapy of <i>Haemophilus</i> spp. Bronchopulmonary Infections. DENNIS G. DELGADO,* CARMEN J. BRAU, C. GLENN COBBS, AND WILLIAM E. DISMUKES	807

Errata

New Rapid Bioassay of Gentamicin Based on Luciferase Assay of Extracellular ATP in Bacterial Cultures. LENNART NILSSON	839
Large-Scale Production and Concentration of Human Lymphoid Interferon. FREDERICK KLEIN, ROBERT T. RICKETTS, WILLIAM I. JONES, IRA A. DEARMON, MATTHEW J. TEMPLE, KATHYRN C. ZOON, AND PAMELA J. BRIDGEN	839
Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against <i>Staphylococcus aureus</i> . JOHN Y. JACOBS, JACQUES MICHEL, AND THEODORE SACKS	839

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
January	23 January 1979	1-145
February	15 February 1979	147-323
March	23 March 1979	325-496
April	20 April 1979	497-633
May	7 May 1979	635-746
June	1 June 1979	747-839

AUTHOR INDEX

VOLUME 16

- Abbott, Bernard J., 808
Abrutyn, Elias, 638
Adair, Frank W., 417
Al-Asadi, Mohammad J. S., 77
Alexander, Michael R., 767
Allen, John G., 306
Alonso, M. A., 750
Alvarez, J. S., 523
Ammer, Johannes, 801
Andrews, J. M., 341
Anthony, Bascom F., 214
Appel, Gerald B., 788
Arioli, Vittorio, 736
Arisawa, Mikio, 444
Armstrong, Emma L., 240
Aruffo, John F., 655
Ash, Ronald J., 301
Aswapokee, N., 164
Aswapokee, Naline, 141, 150
Aswapokee, P., 164
Aswapokee, Prasit, 141, 150, 592
- Badal, R. E., 378
Baker, C. N., 378
Banck, Göran, 554
Bannatyne, Robert M., 43
Barnishan, Jean, 434, 622
Barr, P. J., 234, 680
Barry, A. L., 378
Barry, Arthur L., 495, 823
Barza, Michael, 287
Bawdon, Roger E., 664
Bayer, Arnold S., 112
Beaty, Harry N., 584
Bedford, K. A., 341
Bennett, P. M., 225
Bennett, William M., 231
Bergan, T., 651
Bergström, Sven, 427
Best, Gary K., 134
Bhend, Hansjörg, 127
Bieth, Gilda, 686
Billiau, Alfons, 49, 56
Bland, Judith A., 525
Blaser, Jürg, 127
Bloom, Kim, 572
Bodey, Gerald P., 792
Bolzoni, Giuliana, 736
Bongaerts, Ger P. A., 757
Booth, James A., 277
Borden, Ernest C., 203
Bougueleret, Lydie, 686
Boulton, Michael G., 325, 533
Bourbeau, P., 858
Bradac, James A., 353
Bradley, S. G., 674
Bradshaw, Major W., 655
Brady, Eileen, 266
- Bradshaw, Major W., 655
Brau, Carmen J., 864
Brennenstuhl, Margarete, 801
Briggs, Bruce R., 869
Britz, M. L., 19
Brodwall, E. K., 651
Brown, Christine A., 28
Burch, Keith H., 386
Bury, Ross W., 529
Bush, James A., 398
- Came, Paul E., 813
Canfield, Craig J., 710
Cardenas, Julio, 386
Carniti, Giuliana, 736
Carrasco, L., 750
Carson, D., 858
Carter, Anthony J., 362
Cassiman, Jean-Jacques, 49
Caudry, Suzanne D., 701
Chalhub, Elias G., 171
Chan, John K., 98
Cheung, Rose, 43
Chou, Dong-Lang, 660
Chow, Anthony W., 112
Chulay, Jeffrey D., 710
Cleary, Thomas G., 829
Cobbs, C. Glenn, 353, 353
Cobbs, Glenn C., 864
Collins, M. S., 123
Concepcion, Nelydia F., 112
Condon, R. G., 589
Cooksey, Robert C., 514
Coppens, L., 366
Cort, Winifred M., 372
Counts, George W., 64
Coyle, Marie B., 525
Craft, J. Carl, 346
Crooke, Stanley T., 398
Crues, John V., III, 690
Culbert, Steve, 829
Curtis, Nigel A. C., 325, 533
Custer, Galen M., 869
- Dalovisio, Joseph R., 611
Daneo-Moore, L., 858
Danner, David, 468
Davidson, Leslie A., 104
Debono, Manuel, 808
de Clercq, E., 234, 680
De Clercq, Erik, 56
Delbos, Françoise, 686
Del Busto, Ramon, 386
De Ley, Marc, 49
Delgado, Dennis G., 864
Demierre, Georges, 252
Descamps, J., 234, 680
Desjardins, Robert E., 710
- de Somer, P., 234
De Somer, Piet, 49, 56
DeStefano, Eugene, 266
Dinwiddie, C. B., 491
Dismukes, William E., 353, 864
Dobson, Richard A., 813
Dorman, Douglas E., 808
Doughtery, Susan S., 46
Douglas, R. Gordon, Jr., 644
Dull, William L., 767
Durfee, Marcia A., 635
Dutky, Samson R., 81
- Edmiston, C. E., 862
Edy, Victor G., 49, 56
Ehret, Josephine M., 69
Eickhoff, Theodore C., 69
Ein, Michael E., 655
El-Solh, Névine, 686
Eriquez, Louis A., 392
Everett, E. Dale, 322
- Fabian, Raymond J., 813
Farhner, Lester, 808
Fass, Robert J., 434, 503, 622
Feingold, David S., 660
Feingold, Davis S., 486
Fekety, R., 167
Feldman, William E., 346
Felegie, Terrance P., 833
Fink, F. N., 271
Fisher, Evelyn J., 386
Fletcher, D. D., 271
Flournoy, D. J., 641
Forsgren, Arne, 554
Forsyth, Patricia S., 635
Francke, Elliot L., 788
Frankel, Lawrence S., 829
Freedman, Lawrence R., 252
Friedman-Kien, Alvin E., 266
Frimodt-Møller, N., 406
Frimodt-Møller, Niels, 411
Fu, Kwung P., 141, 150, 561, 592
Fuchs, Peter C., 823
Fujimura, Setsuo, 262
Fukuda, David S., 808
Funnell, Glenn R., 255
- Garrido, M. J., 523
Gaspar, M. N., 190
Gavan, Thomas L., 823
Geftic, Sam G., 417
Gengo, Francis M., 468
Gentry, Layne O., 463
Gerlach, E. H., 378, 772
Gerlach, E. Hugh, 823
Gilbert, David N., 231
Ginsburg, Charles M., 74

AUTHOR INDEX

Glick, Aaron, 615
Goldstein, Beth P., 736
Gorbach, Sherwood L., 287, 565
Gordon, R. C., 862
Goto, Sachiko, 540, 549
Graham, Doris M., 855
Greene, G. R., 198
Greenwood, David, 77
Guinée, P., 237
Guinness, Michael D. G., 255
Guze, Lucien B., 112

Hafkin, Barry, 781
Hagan, Anne C., 301
Hagel, Robert B., 372
Hahon, Nicholas, 277
Hale, Judith A., 635
Hall, William J., 644
Hamilton, R. H., 293
Harris, L. S., 674
Havas, Ladislus, 306
Hayden, Frederick G., 644
Haynes, J. David, 710
Hector, R., 123
Heerema, Mark S., 655, 798
Henney, Jane, 792
Heremans, Hubertine, 56
Heymann, Hans, 417
Higashide, Eiji, 101
Higbee, James W., 322
Hildebrandt, J. F., 336
Ho, Irwin, 592
Hoeprich, Paul D., 217
Holmes, King K., 635
Holtje, Joachim-Volker, 801
Horodniceanu, Théa, 686
Hottendorf, Girard H., 615
Houghton, Donald C., 231
Hau, Patricia C., 525
Hughes, Walter T., 333

Iltis, Jeffrey P., 92
Imagawa, David T., 214
Isaacs, L. L., 491
Ishiguro, Edward E., 849
Iwaya, Makoto, 849

Jackola, D., 9
Jacobs, John Y., 761
Jacobs, M. R., 190
Jacobs, Patricia F., 631
Jacobson, Jay A., 183
Jacobus, Nilda V., 287
Jacoby, George A., 243
Johnson-Thompson, Marian, 667
Jones, A. S., 234, 680
Jones, David T., 724
Jones, R. N., 378
Jones, Ronald N., 823
Jordan, William M., 792
Jusko, William J., 468

Kalyanpur, M. G., 589
Kamimura, Toshiaki, 540

Kampelmacher, E. H., 237
Karr, Stephen L., Jr., 217
Kasik, John E., 767
Kaye, Donald, 283
Ketchel, Steven J., 792
Kiani, Daria, 386
Kilburn, James O., 240
Kim, Kwang Sik, 214
Kitano, Kazuaki, 838
Klastersky, J., 366
Klein, Richard J., 266
Klein, Robert S., 314
Knight, Vernon, 572
Koeppel, Peter, 1
Kohl, Steve, 829
Kojo, Hitoshi, 549
Koonhof, H. J., 190
Kotani, Shozo, 439
Krakowiak, Janet, 664
Kramer, William G., 829
Kung, Ket, 150
Kunin, Calvin M., 519
Kuninaka, Akira, 158
Kunugi, Keith A., 240
Kuwahara, Shogo, 540, 549
Kwung, P. F., 164

Lampe, Mary F., 458
Lane, Timothy W., 638
Lee, B. K., 589
Lee, Kenneth K., 217
LeFrock, Jack L., 98
Leicht, Ernst, 306
Lenox-Smith, Ian, 306
Leonhardt, Peggy H., 203
Lerner, Stephen A., 598
Levison, Matthew E., 283
Lichtenwalner, Diane M., 210, 579
Lin, Tai-Shun, 92
Lode, Hartmut, 1
Lorber, Bennett, 210, 579
Lowy, Franklin D., 314
Luft, F. C., 491
Luft, Friedrich C., 683
Lüthy, Ruedi, 127

Machida, Haruhiko, 158
Madhavan, Tom, 386
Madsen, Paul O., 411
Madsen, P. O., 406
Maigaard, S., 406
Maigaard, Svend, 411
Mangione, Antoinette, 468
Manos, John P., 631
Manten, A., 237
Martin, Robert R., 463
Maruyama, Hiromi B., 444
Mashford, Maurice L., 529
Matsubara, N., 731
Matsumoto, Yoshimi, 540
Matthijssen, Charles, 592
Mayer, Gerald D., 301
Mayers, Marguerite M., 314
McBain, Jack A., 203

ANTIMICROB. AGENTS CHEMOTHER.

McCarthy, Laurence R., 186
McCarthy, L. R., 120
McCracken, George H., Jr., 74
McDonald, Peter J., 695, 695
Merigan, Thomas C., 781
Michel, Jacques, 761
Mickelsen, Patricia A., 186
Miles, Helen M., 529
Miller, G. R., 772
Minami, S., 731
Mine, Yashuiro, 540
Minshew, Barbara H., 458, 525
Mithal, Y., 190
Mitsuhashi, S., 731
Miyamura, Sadao, 719
Mizoguchi, Junzo, 439
Moellering, Robert C., Jr., 690
Mombelli, G., 366
Mong, Seymour, 398
Monson, Thomas P., 776
Mossie, Kevin G., 724
Mouton, R. Peter, 757
Münch, Reiner, 127
Muraoka, T., 731
Murray, Barbara E., 690
Musher, Daniel M., 798

Nagabhushan, T. L., 589
Nakagawa, Yoji, 719
Nakamura, Takeshi, 262
Nakayama, Chikao, 158
Nash, Donna G., 171
Nelson, John D., 346
Neu, Harold C., 141, 150, 164, 561, 592, 625, 788
Niebloom, Theodore A., 452
Nielsen, Richard L., 683
Nisbet, Ian T., 855
Nisbet, Louis J., 306
Nishida, Minoru, 540, 549
Nitahara, Yoshiyuki, 719
Nolan, Charles M., 171, 776
Nolan, R. D., 336
Normark, Staffan, 427
Northrop, Dexter B., 221
Nouravarsani, Roya, 772

Oberhofer, Thomas R., 322
Occolowitz, John L., 808
O'Connor, John R., 813
O'Grady, Francis, 77
Okada, Naohiko, 540
O'Keefe, J. Paul, 565
Orr, David, 325, 533
Overturf, G. D., 198
Ozawa, Takeshi, 683

Palchaudhuri, Sunil, 664
Palmer, W. Martin, 183
Pankey, George A., 611
Panwalker, Anand P., 297
Pappagianis, D., 123
Parker, Richard A., 231
Parker, Roger A., 301
Patel, M., 589

- Perkins, Harold R., 28
 Perlin, Michael H., 598
 Perryman, Fred A., 641
 Petrocheilou, V., 225
 Pfeffer, Morris, 615
 Phaneuf, Denis, 625
 Phillips, L. E., 463
 Pickering, Larry K., 829
 Pisano, Michael A., 392
 Piwowarski, Janet M., 176
 Plamp, Charles E., 231
 Plaut, Martin E., 468
 Pohlod, Donald, 386
 Pollard, Richard B., 781
 Pootjes, Christine F., 293
 Porter, George A., 231
 Pringle, H. L., 674
 Prober, Charles G., 46
 Prusoff, William H., 92
 Pruul, Hendrik, 695
 Purdy, Michael A., 247
 Pyckavet, M., 109

 Quinn, Edward L., 386

 Rahal, James J., Jr., 13
 Rankin, L. L., 491
 Rao, Bhavani, 605
 Rapp, Fred, 92
 Rashtchian, Ayoub, 772
 Raynor, Robert H., 134
 Regueiro, B., 523
 Reinhardt, Albert, 421
 Remington, J., 123
 Reyman, Michael T., 353
 Richmond, M. H., 225
 Ripamonti, I. Franca, 736
 Robb, Frank T., 724
 Robins-Browne, R. M., 190
 Robinson, David B., 98
 Robinson, William S., 781
 Rodriguez, Victorio, 792
 Rogers, T. E., 463
 Rosenthal, Leonard J., 667
 Ross, Gordon W., 325, 533
 Rozmiej, Elzbieta, 664
 Rumans, Larry W., 833

 Sack, C. M., 510
 Sacks, Theodore, 761
 Saikawa, I., 731
 Sakata, Shinji, 158
 Sande, M. A., 271
 Sands, Jeffrey A., 421
 Saneyoshi, Mineo, 158
 Santos, Jose L., 183
 Saravolatz, Louis D., 386
 Sawada, Toyooki, 444
 Scarbrough, Emanuel, 221
 Scheifele, D. W., 510
 Scheld, W. M., 271
 Schell, Ronald F., 98
 Schentag, Jerome J., 468

 Schindler, Peter, 801
 Schmidt, L. H., 475
 Scott, David F., 134
 Scott, Jack K., 424
 Shaw, Paul D., 176
 Sherris, John C., 458
 Shimonaski, G., 589
 Shugar, D., 680
 Siegenthaler, Walter, 127
 Silva, J., Jr., 167
 Simberkoff, Michael S., 13
 Simonson, L. G., 9
 Sisler, Hugh D., 81
 Sloan, R. S., 491
 Smith, A. L., 510
 Smith, E. Grover, 186
 Smith, Nedra J., 655
 Smith, Roy E., 869
 Smith, Thomas F., 106
 Smyth, Robert D., 615
 Snipes, Wallace, 421
 Socransky, Sigmund S., 452
 Someya, Akira, 87
 Sommers, Herbert M., 823
 Spears, Joseph C., 424
 Speers, Donna M., 644
 Spicer, Paul E., 855
 Stahlmann, Ralf, 1
 Stanisich, Vilma A., 701
 Steigbigel, Neal H., 314
 Steinkraus, G. E., 120
 Stephens, James L., 519
 Stevens, Dennis L., 322
 Stewart, John D., 277
 Strong, James E., 398
 Sud, Inder J., 660
 Sud, Inder Jit, 486
 Sugar, Alan M., 210, 579
 Sugimoto, Yoshikazu, 329
 Suginaka, Hidekazu, 439
 Suh, Byungse, 210, 519, 579
 Sullivan, Edna M., 565
 Sutter, Vera L., 495
 Sutton, Lorraine, 243
 Swenson, Jana M., 514
 Syriopoulou, V. Ph., 510

 Takayama, Kuni, 104, 240
 Tally, Francis P., 287, 565
 Tanaka, Kenji, 87
 Tanaka, Nobuo, 87
 Tanida, Seiichi, 101
 Thadepalli, H., 605
 Thompson, R. J., 293
 Thornsberry, C., 378
 Tibbs, G. John, 855
 Tiku, Moti L., 781
 Tomasz, Alexander, 838
 Torrence, P. F., 680
 Toshniwal, R., 167
 Toyoshima, Shigeshi, 329
 Trager, Gary M., 297
 Trestman, Irwin, 283

 Turck, Marvin, 64
 Turley, William, 849

 Ulmer, W. Clyde, Jr., 776

 Van Damme, Jo, 49
 Van den Berge, Herman, 49
 van Embden, J., 237
 van Gestel, Mariette, 757
 Van Harken, Donald R., 615
 Van Landuyt, H. W., 109
 Van Leeuwen, W. J., 237
 Van Leuven, Fred, 49
 van Schothorst, M., 237
 Vaudaux, Pierre, 743
 Vázquez, D., 750
 Verbist, Ludo, 115
 Voogd, C. E., 237
 Voeti, Kenneth L., 46

 Wagner, Roland B., 813
 Waitz, J. A., 589
 Walder, Mats, 37
 Waldvogel, Francis A., 743
 Walker, Clay B., 452
 Walker, R. T., 234, 680
 Wallace, Richard J., 611
 Walsh, Julia A., 314
 Walters, Elwanda, 584
 Waysek, Edward H., 372
 Wehrle, P. F., 198
 Weinstein, R., 858
 Welling, Peter G., 411
 White, G. Wesley, 297
 Wiik-Larsen, E., 651
 Wilkins, Tracy D., 495
 Wilkinson, R. G., 19
 Williams, Jeffrey W., 221
 Williams, Temple W., Jr., 655, 798
 Williams, Tommy, 7
 Wills, P. J., 40
 Wilson, R. Keith, 572
 Wilson, Samuel Z., 572
 Winely, Carl L., 424, 421
 Wise, R., 40, 341
 Wolen, Robert, 683
 Woloshuk, Charles P., 81
 Wong, Ming M., 217
 Woods, David R., 724

 Yamauchi, T., 171
 Yeager, Anne S., 46
 Yee, Robert B., 833
 Yielding, K. Lemone, 247
 Yoge, Ram, 7
 Yoneda, Masahiko, 101
 Yoshimori, Robert N., 214
 Yoshino, Hiroshi, 158
 Yu, Victor L., 833
 Yum, M. N., 491

 Zabransky, Ronald J., 495
 Zahner, Hans, 801

SUBJECT INDEX

VOLUME 16

- Acinetobacter calcoaceticus* subsp. *anitratus*
doxycycline, 690
Herellea vaginicola, 690
minocycline, 690
tetracycline, 690
- Adenine arabinoside
cellular immune responses, 781
hepatitis B virus infection, 781
- Aflatoxin inhibition
viral interferon induction, 277
- Agar diffusion, single-disk
piperacillin susceptibility tests, 378
- Agar disk diffusion susceptibility
azlocillin, 625
carbenicillin, 625
mezlocillin, 625
piperacillin, 625
ticarcillin, 625
- Agrobacterium radiobacter*
agrocin 84, 293
- Agrocin 84
A. radiobacter, 293
purification and characterization, 293
- Alafosfalin
animals, 306
humans, 306
inhibition of cell wall biosynthesis, 444
 β -lactams, 444
metabolism and pharmacokinetics, 306
phosphonopeptides, 306
urinary isolates, 444
- 5-Alkyl derivatives
antiherpesviral activity, 158
1- β -D-arabinofuranosyluracil, 158
- Alpha-aminoadipic acid
peptides, 392
P. persicus P-10, 392
- Amantadine
aerosol, 572
aerosols, 644
humans, 572
normal volunteers, 644
safety testing, 644
- Amikacin
bronchial secretions, 767
children with malignancy, 829
compared with fortimicin A, 823
compared with SCH 21420, 491
E. coli, 598
in vitro susceptibility, 823
kanamycin acetyltransferase, 221
nephrotoxicity, 491
plasmid-borne aminoglycoside
phosphotransferase, 598
rats, 491
spectrophotometric assay, 221
- Aminoglycoside
gram-negative bacillary disease, 353
serum concentrations, 353
- Aminoglycoside nephrotoxicity
organic acids and bases, renal transport, 231
- Aminoglycoside phosphotransferase
amikacin resistance, 598
E. coli, 598
- Aminoglycosides
lymphocyte function, 554
renal tubular damage, 468
- p-Aminohippurate
aminoglycoside nephrotoxicity, 231
renal transport, 231
- 6-Aminopenicillanic acid
E. coli, 849
temperature sensitivity, 849
- Ammonia
suppressed by bowel flora, 519
- Amoxicillin
bacterial meningitis, 171, 346
- ampC
Chromosomal β -lactamase, 427
- Amphotericin B
C. lusitanae, 123
methyl ester, 203, 217
N. fowleri strain HB-1, 217
plus minocycline, 217
plus tetracycline, 217
polyinosinic:polycytidylic acid, 203
resistance in a human, 123
- Amphotericin 1 15B
C. lusitanae, 123
- Ampicillin
bacterial meningitis, 198
Bacteroides sp., 283
Enterobacter, 458
experimental meningitis, 584
H. influenzae, 198
P. multocida, 322
rabbits, 584
synergism with mecillinam, 283
- Ampicillin and dicloxacillin
C. freundii, 439
combined, synergistic action, 439
 β -lactamase-producing strain, 439
- Anaerobic bacteria
reference dilution susceptibility testing, 495
sodium fusidate, 120
- Ansamitocins
antitumor antibiotics, 101
cilia regeneration, 101
Tetrahymena, 101
- Antibiotic susceptibility disk
high-pressure liquid chromatography analysis, 372
- Antibiotic susceptibility testing

- Autobac, 98
 Autobac I, 255
 calibrated dichotomous sensitivity disk diffusion, 255
 Fildes enrichment, 98
H. influenzae, 98
 Anti-herpes agents
 athymic nude mice, 680
 cutaneous herpes simplex virus, 680
 Antiherpesviral activity
 5-alkyl derivatives, 158
 1- β -D-arabinofuranosyluracil, 158
 Antimalarial activity
 P. falciparum, 710
 semiautomated microdilution technique, 710
 Antimicrobial inhibition patterns
 nutritionally variant streptococci, 514
 Antineoplastic antibiotics
 bleomycin, 761
 gram-negative bacilli, 761
 mitomycin C, 761
 Antirhinovirus compound
 RMI 15,731, 301
 1-[5-tetradecyloxy-2-furanyl]-ethanone, 301
 Antitumor compounds
 covalently closed circular DNA, 398
 PM-2 DNA, 398
 prescreening, 398
 1- β -D-Arabinofuranosyluracil
 5-alkyl derivatives, 158
 Arteriovenous fistula
 infection, induction, 638
 prevention, 638
 Athymic nude mice
 anti-herpes agents, 680
 cutaneous herpes simplex virus, 680
 Autobac I
 Australia, 255
 interpretive modifications, 255
 rapid antibiotic susceptibility testing, 255
 technical modifications, 255
 Autolytic cell wall degradation
 E. coli, 838
 β -lactam antibiotics, 838
 Azacytidine
 nucleoprotein complexes, 667
 simian virus 40, 667
 Azasteroid antibiotic
 15-aza-24-methylene-D-homocholesta-8,14-dien-3 β -ol, 81
 U. maydis, 81
 15-Aza-24-methylene-D-homocholesta-8,14-dien-3 β -ol
 azasteroid antibiotic, 81
 U. maydis, 81
 Azlocillin
 agar disk diffusion susceptibility, 625
 gram-negative organisms, 115
 A23187
 divalent cation ionophore antibiotic, 808
 microbial transformation, 808
 Bactec 460
 compared with radioimmunoassay, 463
 Bacteria exposure
 antimicrobial drugs, 77
 infection, 77
 in vitro model simulating exposure, 77
 Bacterial meningitis
 amoxicillin, 171, 346
 ampicillin, 198
 H. influenzae, 198
 probenecid, 346
 Bacteriocin
 B. fragilis, 724
 Bacteroides
 cephalosporin inactivation, 565
 Bacteroides fragilis
 Detroit hospitals, 664
 low-molecular-weight bacteriocin, 724
 LY127935, 287
 metronidazole-resistant mutants, 19
 susceptibility pattern, 664
 Bacteroides sp.
 mecillinam, 283
 semisynthetic penicillins, 283
 Bay K 4999
 Bacteroides sp., 283
 gram-negative organisms, 115
 synergism with mecillinam, 283
 Beta-lactam antibiotic
 LY127935, 297
 Beta-lactam antibiotics
 autolytic cell wall degradation, 838
 E. coli, 838
 Beta-lactamase
 anaerobic conditions, 772
 E. coli, 772
 increased production, 772
 Bicyclomycin
 E. coli, 87
 morphological changes, 87
 Biosynthetic pathway
 gentamicin C_{2a}, 589
 M. purpurea SC 1210, 589
 Bleomycin
 combined with aminoglycosides, 761
 combined with β -lactams, 761
 gram-negative bacilli, 761
 Blood coagulation
 cefamandole nafate, 869
 E-5-(2-bromovinyl)-2'-deoxyuridine
 mice, 234
 Bronchial secretions
 amikacin, 767
 Butikacin (UK-18,892)
 cochlear toxicity, 362
 guinea pigs, 362
 semisynthetic aminoglycoside, 362
 Campylobacter fetus subsp. jejuni
 doxycycline, 37
 gentamicin, 37
 Cancer patients
 fungal infections, 792
 miconazole, 792
 Candida albicans
 experimental endocarditis, 252
 5-fluorocytosine, 252
 rabbits, 252
 Candida lusitanae
 amphotericin B resistance, 123

- human, 123
- Carbenicillin
 - agar disk diffusion susceptibility, 625
 - Bacteroides* sp., 283
 - P. multocida*, 322
 - synergism with mecillinam, 283
- Cation ionophore antibiotic A23187, 808
- Cefaclor
 - pharmacokinetics, 1
- Cefadroxil
 - pharmacokinetics, 1
- Cefamandole
 - antibacterial activity, 64
 - Bacteroides*, 565
 - cefazolin, 112
 - ceforamide, 64
 - cephaloridine, 112
 - compared with cefamandole nafate, 424
 - experimental meningitis, 584
 - inactivation, 565
 - lactobacilli, 112
 - microbiological assay, 424
 - parenteral cephalosporin, 64
 - rabbits, 584
- Cefamandole nafate
 - blood coagulation, 869
 - compared with cefamandole, 424
 - dialysis patients, 683
 - hydrolysis, 683
 - microbiological assay, 424
 - platelet function, 869
- Cefazolin
 - Bacteroides*, 565
 - cefamandole, 112
 - cephaloridine, 112
 - high doses, 615
 - inactivation, 565
 - lactobacilli, 112
 - pharmacokinetics, 615
- Cefoperazone
 - comparative activity, 150
 - β -lactamase stability, 150
 - piperazine cephalosporin, 150
- Cefoperazone (T-1551)
 - in vitro activity, 731
 - semisynthetic cephalosporin, 731
- Ceforanide
 - clinical evaluation, 386
 - in vitro evaluation, 386
- Ceforanide (BL-S786R)
 - high doses, 615
 - pharmacokinetics, 615
- Cefotaxime
 - activity, 757
 - β -lactamase stability, 757
 - compared with six other cephalosporins, 757
 - diffusion disk susceptibility test, 164
 - intramuscularly, 592
 - intravenously, 592
 - pharmacokinetics, 592
- Cefotaxime (HR 756)
 - human pharmacology, 127
- Cefoxatime
 - cephalothin-resistant clinical isolates, 109
- Cefoxitin
 - aerobic infection, 366
 - cancer patients, 366
 - compared with clindamycin, 366
- Cefoxitin therapy
 - children, 183
 - clinical and bacteriological evaluation, 183
- Ceftizoxime (FK 749)
 - antibacterial activities, 540
 - antibacterial activity, 549
 - cephalosporin-resistant bacteria, 549
 - β -lactamase stability, 549
 - new parenteral cephalosporin, 540
- Cell wall biosynthesis
 - alafosfalin, 444
- Cephalexin
 - pharmacokinetics, 1
- Cephalexidine
 - cefamandole, 112
 - cefazolin, 112
 - lactobacilli, 112
- Cephalosporin
 - Bacteroides*, 565
 - cefoperazone (T-1551), 731
 - cefotaxime (HR 756), 127
 - ceftizoxime (FK 749), 540, 549
 - cephalosporin-resistant bacteria, 549
 - inactivation, 565
- Cephalosporins
 - affinities with penicillins, 533
 - antibacterial activities, 533
 - cefotaxime, 757
 - E. coli* K-12 penicillin-binding proteins, 533
 - lymphocyte function, 554
- Cephalothin
 - Bacteroides*, 565
 - inactivation, 565
 - P. multocida*, 322
- Cephalothin-resistant clinical isolates
 - cefotaxime, 109
- Cephadrine suspension
 - infants and children, 74
 - pharmacokinetics, 74
- Cerulenin
 - S. faecalis* (*S. faecium*)
- CGP 9000
 - pharmacokinetics, 1
- Chicken carcasses
 - antibiotic-resistant *E. coli*, 701
 - conjugative R plasmids, 701
 - frozen, 701
- Children
 - amikacin, 829
 - malignancy, 829
- Chlamydia trachomatis*
 - chlorhexidine, 855
- Chloramphenicol
 - bactericidal action, 13
 - bacteriostatic action, 13
 - bioassay, 43
 - E. coli*, 695
 - enzymatic acetylation, 719
 - infants, 7
 - Kirby-Bauer breakpoints, 190
 - leukocyte activity, 695
 - lymphocyte function, 554
 - meningeal pathogens, 13

- P. multocida*, 322
 pneumococci, 190
S. faecalis, 719
 ventricular fluid levels, 7
- Chlorhexidine
Chlamydia trachomatis, 855
 in vitro and in vivo, 855
- Chronic hemodialysis
 piperacillin, 788
- Cilia regeneration
 ansamitocins, 101
 antitumor antibiotics, 101
Tetrahymena, 101
- Cinoxacin
 impaired renal function, 411
 pharmacokinetics, 411
 tolerance, 411
- Citrobacter freundii*
 ampicillin and dicloxacillin, synergism, 439
 β -lactamase-producing strain, 439
- Clavulanic acid
 mice, 798
S. aureus renal infection, 798
- Clindamycin
 aerobic infection, 366
 cancer patients, 366
 compared with cefoxitin, 366
 Kirby-Bauer breakpoints, 190
 pneumococci, 190
 resistance in *C. diphtheriae*, 525
 skin lesions, 525
- Cochlear toxicity
 butikacin (UK-18,892), 362
 guinea pigs, 362
- Na-Cocoyl-L-arginine ethyl ester*
 hepatitis B surface antigen, 329
 DL-pyroglutamic acid salt, 329
- Corynebacterium diphtheriae*
 clindamycin resistance, 525
 erythromycin resistance, 525
 skin lesions, 525
- Corynebacterium vaginale*
 antibiotic susceptibility, 186
H. vaginalis, 186
- Covalently closed circular deoxyribonucleic acid
 prescreening antitumor compounds, 398
- Cutaneous herpes simplex virus
 anti-herpes agents, 680
 athymic nude mice, 680
- Dextranases
 hydroxyapatite, 9
S. mutans, 9
- Dialysis patients
 cefamandole nafate, 683
- Dicarboxylic acids
 lytic effect, 417
P. aeruginosa, 417
 plus sodium dodecyl sulfate, 417
- Diffusion disk susceptibility test
 cefotaxime, 164
- Dihydroacridinedione derivative
 antimalarial properties, 475
 floxacrine, 475
- Disk diffusion susceptibility testing
 antibacterial agents, 611
- M. chelonae*, 611
M. fortuitum, 611
- Divalent cation concentrations
 antibiotic susceptibilities, 434
 nonfermenters, 434
P. aeruginosa, 434
- Doxycycline
A. calcoaceticus subsp. *anitratus*, 690
C. fetus subsp. *jejuni*, 37
- Enterobacter*
 ampicillin, 458
 in vitro, 458
- Enterobacteriaceae* meningitis
 mecillinam-ampicillin synergism, 271
- Enzymatic acetylation
 chloramphenicol, 719
S. faecalis, 719
- Enzyme immunoassay
 gentamicin, 40
- Erythromycin
 acidity of vaginal secretions, 635
H. vaginalis-associated vaginitis, 635
 Kirby-Bauer breakpoints, 190
 pneumococci, 190
 resistance in *C. diphtheriae*, 525
 skin lesions, 525
 urinary tract pathogens, 69
- Escherichia coli*
 amikacin resistance, 598
 aminoglycoside phosphotransferase, 598
 6-aminopenicillanic acid-resistant mutants, 849
 ampC-mediated chromosomal β -lactamase, 427
 anaerobic conditions, 772
 antibiotic resistance, 701
 autolytic cell wall degradation, 838
 beta-lactamase, 772
 bicyclomycin, 87
 chloramphenicol, 695
 conjugative R plasmids, 701
 frozen chicken carcasses, 701
 β -lactam antibiotics, 838
 β -lactamase resistance, 427
 leukocyte activity, 695
 morphological changes, 87
 phosphoenolpyruvate-sugar phosphotransferase system, 801
 phosphorylation, 801
 plasmid-carrying tetracycline-resistant, 225
- Escherichia coli* ATCC 25922
 34 antimicrobial agents, 622
 minimal inhibitory concentration, 622
- Escherichia coli* K-12
 affinities of penicillins and cephalosporins, 533
 gyrase inhibitors, 247
 gyrase-recBC deoxyribonuclease function, 247
 penicillin-binding proteins, 533
 post-ultraviolet killing, 247
- Ethambutol
M. smegmatis, 240
 mycolic acid transfer, 240
- Experimental arteriovenous fistula infection
 induction, 638
 prevention, 638
- Experimental endocarditis
C. albicans, 252

SUBJECT INDEX

ANTIMICROB. AGENTS CHEMOTHER.

- 5-fluorocytosine, 252
- rabbits, 252
- Experimental meningitis
 - ampicillin, 584
 - cefamandole, 584
 - rabbits, 584
- Fildes enrichment
 - antibiotic susceptibility testing, 98
 - H. influenzae*, 98
- Floxacin
 - antimalarial properties, 475
 - dihydroacridinedione derivative, 475
- Flucytosine
 - assay by high-pressure liquid chromatography, 529
 - 5-fluorocytosine, assay, 529
 - human plasma, 529
- Fluorocytosine
 - lymphocyte function, 554
- 5-Fluorocytosine
 - c. albicans*, 252
 - flucytosine, 529
 - high-pressure liquid chromatography, 529
 - human plasma, 529
 - rabbits, 252
- Fortimicin A
 - compared with amikacin and gentamicin, 823
 - in vitro susceptibility, 823
- Free fatty acids
 - imidazole antifungals, 660
 - liposome susceptibility, 660
- Fungal infection
 - cancer patients, 792
 - miconazole, 792
- Gentamicin
 - antibacterial activity, 743
 - C. fetus* subsp. *jejuni*, 37
 - compared with fortimicin A, 823
 - experimental murine listeriosis, 862
 - high-level, plasmid-borne resistance, 686
 - human polymorphonuclear leukocytes, 743
 - in vitro susceptibility, 823
 - rapid simple enzyme immunoassay, 40
 - S. faecalis* subsp. *zymogenes*, 686
 - with penicillin synergistically, 862
- Gentamicin C₂
 - biosynthetic pathway, 589
- Gram-negative bacillary disease
 - aminoglycoside, 353
 - serum concentrations, 353
- Gram-negative bacilli
 - antimicrobial drugs, 761
- Group B streptococci
 - penicillin tolerance, 214
- Gyrase inhibitors
 - E. coli* K-12, 247
 - gyrase-*recBC* DNase function, 247
- Gyrase-*recBC* DNase function
 - E. coli* K-12, 247
 - gyrase inhibitors, 247
- Haemophilus influenzae*
 - ampicillin, 198
 - antibiotic susceptibility testing, 98
 - bacterial meningitis, 198
 - Fildes enrichment, 98
- Haemophilus influenzae* b
 - susceptibility to β -lactam antibiotics, 510
- Haemophilus vaginalis*
 - acidity of vaginal secretions, 635
 - erythromycin, 635
 - vaginitis, 635
- Haemophilus vaginalis* (*Corynebacterium vaginale*)
 - antibiotic susceptibility, 186
- Hamsters
 - pseudomembranous colitis, 167
- Hepatitis B surface antigen
 - N*-cocoyle-L-arginine ethyl ester, 329
 - D,L-pyrogutamic acid salt, 329
- Hepatitis B virus infection
 - adenine arabinoside treatment, 781
 - cellular immune responses, 781
 - interferon treatment, 781
- Herpes simplex virus
 - hairless mice, 266
 - phosphonoformate, 266
 - skin infection, 266
- High-pressure liquid chromatography
 - antibiotic susceptibility disk analysis, 372
 - flucytosine, 529
 - 5-fluorocytosine, 529
- HR 756
 - antibacterial activity, 64
 - compared with cefamandole and ceforanide, 64
 - parenteral cephalosporin, 64
- Human fibroblast interferon
 - characterization, 49
 - clinical trials, 49
 - experimental animals and humans, 56
 - partial purification, 49
 - pharmacokinetics, 56
 - production, 49
 - tolerability, 56
- Human polymorphonuclear leukocytes
 - gentamicin, 743
- Hydroxyapatite
 - dextranases, 9
 - S. mutans*, 9
- Imidazole antifungals
 - free fatty acids, 660
 - liposome susceptibility, 660
- Impaired renal function
 - cinoxacin, 411
- Infants
 - chloramphenicol, 7
 - ventricular fluid levels, 7
- Infants and children
 - cephradine suspension, 74
- Interferon
 - cellular immune responses, 781
 - hepatitis B virus infection, 781
 - human fibroblast, 49, 56
- 5-Iodo-5'-amino-2',5'-dideoxyuridine
 - Varicella-zoster virus, 92
- Isoniazid inhibition
 - monounsaturated long-chain fatty acids, 104
 - M. tuberculosis* H37Ra, 104
- Kanamycin acetyltransferase

- amikacin, 221
spectrophotometric assay, 221
- Klebsiella*
vs. LY127935, 641
- β -Lactam
ampC-mediated chromosomal β -lactamase, 427
N. gonorrhoeae, 28
peptidoglycan, 28
resistance in *E. coli*, 427
- Oxa- β -lactam
 β -lactam antibiotics, 341
LY127935, 341
- β -Lactam antibiotic
Klebsiella, 641
LY127935, 503, 641
Proteus, 641
Pseudomonas, 641
Serratia, 641
- β -Lactam antibiotics
E. cloacae, 325
E. coli, 325
H. influenzae b, 510
K. aerogenes, 325
oxa- β -lactam, 341
LY127935, 341
P. aeruginosa, 243, 325
P. rettgeri, 325
R plasmids, 243
susceptibility, 510
- β -Lactamase
ampC-mediated chromosomal, 427
isolates of *E. coli*, 427
- β -Lactam antibiotics
L. pneumophila, 561
- β -Lactamase stability
ceftizoxime (FK 749), 549
- β -Lactams
alafosfalin, 444
urinary isolates, 444
- Lactobacilli
cefamandole, 112
cefazolin, 112
cephaloridine, 112
- Legionella pneumophila*
inactivation of β -lactam antibiotics, 561
- Leukocyte activity
chloramphenicol, 695
enhancement against *E. coli*, 695
- Lipid composition
P. wickerhamii, 486
- Liposome susceptibility
free fatty acids, 660
imidazole antifungals, 660
- Long-chain fatty acids
isoniazid inhibition, 104
M. tuberculosis H37Ra, 104
- l-Oxa cephalosporin
gram-negative bacilli, 864
LY127935, 864
- Lymphocyte function
suppression, 554
LY127935
activity against 536 clinical isolates, 503
antibacterial activity, 297
beta-lactam antibiotic, 297
- B. fragilis*, 287
gram-negative bacilli, 864
in vitro activity, 287
oxa- β -lactam, 341
 β -lactam antibiotic, 503, 641
 β -lactam antibiotics, 341
l-oxa cephalosporin, 864
P. maltophilia, 833
S. aureus, 287
susceptibility, 833
vs. *Klebsiella*, 641
vs. *Proteus*, 641
vs. *Pseudomonas*, 641
vs. *Serratia*, 641
- Mecillinam
Bacteroides sp., 283
semisynthetic penicillins, 283
Mecillinam-ampicillin synergism
experimental *Enterobacteriaceae* meningitis, 271
- Meningeal pathogens
chloramphenicol, 13
- Methicillin
resistance of *S. epidermidis*, 655
resistant to *S. epidermidis*, 314
S. epidermidis, 314
susceptibility, 655
synergy, 655
- N-methylnicotinamide
aminoglycoside nephrotoxicity, 231
renal transport, 231
- Metronidazole-resistant mutants
B. fragilis, 19
- Mezlocillin
agar disk diffusion susceptibility, 625
Bacteroides sp., 283
clinical evaluation, 605
gram-negative organisms, 115
patients with impaired renal function, 651
patients with normal renal function, 651
synergism with mecillinam, 283
- Mice
E-5-(2-bromovinyl)-2'-deoxyuridine, 234
- Miconazole
cancer patients, 792
fungal infection, 792
- Microdilution technique
antimalarial activity, 710
P. falciparum, 710
- Micromonospora purpurea* SC 1210
biosynthetic pathway, 589
- Minocycline
A. calcoaceticus subsp. *anitratus*, 690
N. fowleri strain HB-1, 217
plus amphotericin B, 217
P. maltophilia, 833
susceptibility, 833
- Mitomycin C
combined with aminoglycosides, 761
gram-negative bacilli, 761
- Murine listeriosis
penicillin and gentamicin synergistically, 862
- Mycobacterium chelonae*
antibacterial agents, 611
disk diffusion susceptibility testing, 611
Mycobacterium fortuitum

SUBJECT INDEX

ANTIMICROB. AGENTS CHEMOTHER.

- antibacterial agents, 611
- disk diffusion susceptibility testing, 611
- Mycobacterium smegmatis*
 - ethambutol, 240
 - mycolic acid transfer, 240
- Mycobacterium tuberculosis* H37Ra
 - monounsaturated long-chain fatty acids, 104
- Mycolic acid transfer
 - ethambutol, 240
 - inhibition, 240
 - M. smegmatis* cell wall, 240
- Naegleria fowleri*
 - susceptibility to Δ^9 -tetrahydrocannabinol, 674
- Naegleria fowleri* strain HB-1
 - amphotericin B methyl ester, 217
 - amphotericin B plus minocycline, 217
 - amphotericin B plus tetracycline, 217
- Nafcillin
 - spectrofluorometry, 210
- Nalidixic acid
 - lymphocyte function, 554
- Neisseria gonorrhoeae*
 - β -lactam-resistant strains, 28
 - β -lactam-sensitive strains, 28
 - penicillin-binding proteins, 329
 - peptidoglycan, 28
- Neomycin
 - oral dosage schedules, 519
 - suppressing ammonia production by bowel flora, 519
- Nephrotoxicity
 - amikacin, 491
 - aminoglycoside, 231
 - p*-aminohippurate, renal transport, 231
 - N*-methylnicotinamide, 231
 - rats, 491
 - SCH 21420, 491
 - Win 42122-2, 813
- Netilmicin
 - complicated urinary tract infection, 406
 - renal function impairment, 406
- Nonfermenters
 - antibiotic susceptibilities, 434
 - divalent cation concentrations, 434
- Nucleoprotein complexes
 - azacytidine, 667
 - simian virus 40, 667
- Ototoxicity
 - Win 42122-2, 813
- 1-Oxa cephalosporin
 - antibacterial activity, 141
 - (6R,7R)-7-[[carboxy(4-hydroxyphenyl)acetyl]-amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)-thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 141
- Oxacillin-induced lysis
 - S. aureus*, 134
- Paecilomyces persicus*
 - intracellular alpha-amino adipic acid-containing peptides, 392
- Parenteral cephalosporin
 - antibacterial activity, 64
 - cefamandole, 64
 - ceforanide, 64
 - ceftizoxime (FK 749), 540
 - HR 756, 64
- Parenteral cephalosporins
 - cefamandole, 112
 - cefazolin, 112
 - cephaloridine, 112
 - lactobacilli, 112
- Pasteurella multocida*
 - ampicillin, 322
 - carbenicillin, 322
 - cephalothin, 322
 - chloramphenicol, 322
 - penicillin G, 322
 - tetracycline, 322
- Penicillin
 - experimental murine listeriosis, 862
 - group B streptococci, 214
 - mice, 798
 - S. aureus* renal infection, 798
 - tolerance, 214
 - with gentamicin synergistically, 862
- Penicillin-binding proteins
 - E. cloacae*, 325
 - E. coli*, 325
 - K. aerogenes*, 325
 - β -lactam antibiotics, 325
 - N. gonorrhoeae*, 336
 - P. aeruginosa*, 325
 - P. rettgeri*, 325
- Penicillin G
 - compared with rosaramicin, 776
 - experimental pneumococcal meningitis, 776
 - Kirby-Bauer breakpoints, 190
 - P. multocida*, 322
 - pneumococci, 190
- Penicillins
 - affinity with cephalosporins, 533
 - antibacterial activities, 533
 - E. coli* K-12 penicillin-binding proteins, 533
 - lymphocyte function, 554
- Peptidoglycan
 - in vitro synthesis, 28
 - β -lactam, 28
 - N. gonorrhoeae*, 28
- Periodontal pockets
 - bacteria, 452
 - human, 452
 - susceptibility testing, 452
- Phosphoenolpyruvate-sugar phosphotransferase
 - E. coli*, 801
- Phosphonoformate
 - hairless mice, 266
 - herpes simplex virus-induced skin infection, 266
- Phosphonopeptides
 - alafosfalin, 306
- Piperacillin
 - agar disk diffusion susceptibility, 625
 - Bacteroides* sp., 283
 - chronic hemodialysis, 788
 - gram-negative organisms, 115
 - synergism with mecillinam, 283
- Piperacillin susceptibility tests
 - single-disk agar diffusion, 378
- Piperazine cephalosporin

- cefoperazone, 150
Plasmodium falciparum
 antimalarial drugs, 710
 semiautomated microdilution technique, 710
 Platelet function
 cefamandole nafate, 869
 PM-2 DNA
 antitumor compound, 398
 Pneumococcal meningitis
 penicillin G, 776
 rosaramicin, 776
 Pneumococci
 antimicrobial susceptibility testing, 190
 chloramphenicol, 190
 clindamycin, 190
 erythromycin, 190
 penicillin G, 190
 rifampin, 190
 tetracycline, 190
Pneumocystis carinii
 trimethoprim-sulfamethoxazole, 333
 Polyinosinic:polycytidylic acid
 amphotericin B methyl ester, 203
 antiviral activity, 203
 Probenecid
 bacterial meningitis, 346
 Protein synthesis
 compounds affecting inhibition, 750
 inhibition, 750
 yeast, 750
Proteus
 vs. LY127935, 641
Prototheca wickerhamii
 lipid composition, 486
 sensitivity to membrane-active antimicrobial agents, 486
 Pseudomembranous colitis
 hamsters, 167
 tetracycline-associated, 167
Pseudomonas
 vs. LY127935, 641
Pseudomonas aeruginosa
 dicarboxylic acids plus sodium dodecyl sulfate, 417
 β -lactam antibiotics, 243
 R plasmids, 243
 tricarboxylic acids plus sodium dodecyl sulfate, 417
Pseudomonas aeruginosa ATCC 27853
 34 antimicrobial agents, 622
 minimal inhibitory concentration, 622
Pseudomonas maltophilia
 LY127935, 833
 minocycline, 833
 susceptibility, 833
 trimethoprim-sulfamethoxazole, 833
 DL-pyroglutamic acid salt
 Na-cocoyl-L-arginine ethyl ester, 329
 hepatitis B surface antigen, 329
 Radioimmunoassay
 compared with Bactec 460, 463
 compared with radiometric assay, 631
 gentamicin, 631
 Radiometric assay
 compared with radioimmunoassay, 631
 gentamicin, 631
 Rat nephrotoxicity
 amikacin, 491
 SCH 21420, 491
 Reference dilution susceptibility testing
 anaerobic bacteria, 495
 Renal function
 mezlocillin, 651
 Renal function impairment
 complicated urinary tract infection, 406
 netilmicin, 406
 Renal infection
 clavulanic acid, 798
 mice, 798
 penicillin, 798
 S. aureus, 798
 Renal tubular damage
 aminoglycosides, 468
 urinary casts, 468
 Retinal
 virucidal activity, 421
 Rifampin
 bactericidal activity, 736
 human urine, 736
 Kirby-Bauer breakpoints, 190
 plus trimethoprim, 736
 pneumococci, 190
 suppression of resistance, 736
 RMI 15,731 (1-[5-Tetradecyloxy-2-furanyl]-ethanone)
 antirhinovirus compound, 301
 Rosamicin
 urinary tract pathogens, 69
 Rosaramicin
 compared with penicillin G, 776
 experimental pneumococcal meningitis, 776
 U. urealyticum, 106
 R plasmids
 antibiotic-resistant *E. coli*, 701
 chicken carcasses, 701
 conjugative, 701
Salmonella
 drug resistance, 237
 The Netherlands, 237
 Sanguicin
 Oral *S. sanguis*, 262
 SCH 21420
 compared with amikacin, 491
 nephrotoxicity, 491
 rats, 491
 Semisynthetic aminoglycoside
 butikacin (UK-18,892), 362
 cochlear toxicity, 362
 guinea pigs, 362
Serratia
 vs. LY127935, 641
Serratia marcescens
 antimicrobial susceptibility, 523
 Serum bactericidal test
 compared with standard tube dilution method, 46
 Serum gentamicin assay
 Bactec assay, 631
 Serum level
 Bactec 460, 463
 tobramycin, 463

SUBJECT INDEX

ANTIMICROB. AGENTS CHEMOTHER.

- Simian virus 40
 - azacytidine, 667
 - nucleoprotein complexes, 667
- Single-disk agar diffusion
 - piperacillin susceptibility tests, 378
- Sodium fusidate
 - anaerobic bacteria, 120
 - in vitro, 120
- Spectrofluorometry
 - nafcillin, 210
 - sulfamethoxazole levels, 579
 - trimethoprim levels, 579
- Standard tube dilution method
 - compared with serum bactericidal test, 46
- Staphylococcus aureus*
 - clavulanic acid, 798
 - LY127935, 287
 - mice, 798
 - oxacillin-induced lysis, 134
 - penicillin, 798
 - renal infection, 798
- Staphylococcus epidermidis*
 - methicillin, 655
 - methicillin resistance, 314
- Streptococci, nutritionally variant
 - antimicrobial inhibition patterns, 514
- Streptococcus faecalis*
 - chloramphenicol acetylation, 719
- Streptococcus faecalis* (S. faecium)
 - antibiotic-induced lysis, 858
- Streptococcus faecalis* (S. faecium)
 - cerulenin, 858
- Streptococcus faecalis* subsp. zymogenes
 - gentamicin, 686
- Streptococcus mutans*
 - attachment to hydroxyapatite, 9
 - dextranases, 9
- Streptococcus sanguis*
 - bacteriocin, 262
 - sanguicin, 262
- Streptomyces bikiniensis*
 - streptomycin resistance, 176
- Streptomycin resistance
 - S. bikiniensis, 176
- Streptozotocin
 - E. coli, 801
 - phosphorylation, 801
- Sulfamethoxazole
 - lymphocyte function, 554
- Sulfamethoxazole levels
 - rapid assay, 579
 - serum, 579
 - spectrofluorometry, 579
- Tetracycline
 - A. calcoaceticus subsp. anitratus, 690
 - Kirby-Bauer breakpoints, 190
 - N. fowleri strain HB-1, 217
 - plasmid-carrying tetracycline-resistant E. coli, 225
 - plus amphotericin B, 217
 - P. multocida, 322
 - pneumococci, 190
- Tetracycline-associated pseudomembranous colitis
 - hamsters, 167
- 1-[5-tetradecyloxy-2-furanyl]-ethanone
 - antirhinovirus compound, 301
- RMI 15,731, 301
- Δ^9 -Tetrahydrocannabinol
 - N. fowleri, 674
- Tetrahymena*
 - ansamitocins, 101
 - cilia regeneration, 101
- The Netherlands
 - Salmonella, 237
- Ticarcillin
 - agar disk diffusion susceptibility, 625
 - Bacteroides sp., 283
 - synergism with mecillinam, 283
- Tobramycin
 - Bactec 460, 463
 - serum levels, 463
- Tricarboxylic acids
 - lytic effect, 417
 - P. aeruginosa, 417
 - plus sodium dodecyl sulfate, 417
- Trimethoprim
 - bactericidal activity, 736
 - human urine, 736
 - lymphocyte function, 554
 - plus trimethoprim, 736
 - suppression of resistance, 736
- Trimethoprim levels
 - rapid assay, 579
 - serum, 579
 - spectrofluorometry, 579
- Trimethoprim-sulfamethoxazole
 - P. carni, 333
 - P. maltophilia, 833
 - prophylaxis, 333
 - susceptibility, 833
- T 1551
 - cefoperazone, 150
 - comparative activity, 150
 - β -lactamase stability, 150
- Ureaplasma urealyticum*
 - rosaramicin, 106
- Ureidopenicillins
 - azlocillin, 115
 - Bay k 4999, 115
 - gram-negative organisms, 115
 - mezlocillin, 115
 - piperacillin, 115
- Urinary isolates
 - alafosfalin, 444
- Urinary tract infection
 - netilmicin, 406
 - renal function impairment, 406
- Urinary tract pathogens
 - erythromycin, 69
 - rosamicin, 69
- Ustilago maydis*
 - azasteroid antibiotic, 81
 - 15-aza-24-methylene-D-homocholesta-8,14-dien-3 β -ol, 81
- Vaginitis
 - acidity of vaginal secretions, 635
 - H. vaginalis, 635
- Varicella-zoster virus
 - 5-iodo-5'-amino-2',5'-dideoxyuridine, 92
- Ventricular fluid levels

VOL. 16, 1979

SUBJECT INDEX

chloramphenicol, 7
infants, 7
Viral interferon induction
aflatoxin inhibition, 277
Virucide
retinal, 421

Win 42122-2
antibacterial activity, 813
nephrotoxicity, 813
ototoxicity, 813

Yeast
protein synthesis, 750



ANTIMICROBIAL AGENTS
AND
CHEMOTHERAPY

VOLUME 16

WASHINGTON, DC 20006

1979

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VOLUME 16 • 1979

EDITORIAL BOARD

GLADYS L. HOBBS, *Editor-in-Chief* (1980)
Infectious Disease Research Institute, Livingston, N.J.

WALTER D. CELMER, *Editor* (1980)
Pfizer Inc., Groton, Conn.

HERBERT L. ENNIS, *Editor* (1982)
*Roche Institute of Molecular Biology,
Nutley, N.J.*

JOEL G. FLAKS, *Editor* (1981)
University of Pennsylvania, Philadelphia

EDWARD W. HOOK, *Editor* (1981)
University of Virginia, Charlottesville

LEON H. SCHMIDT, *Editor* (1981)
Southern Research Institute, Birmingham, Ala.

Vincent T. Andriole (1981)
John P. Anhalt (1981)
Donald Armstrong (1980)
Robert Austrian (1980)
Arthur L. Barry (1980)
John E. Bennett (1981)
Lawrence E. Bryan (1979)
D. Buyske (1980)
Yves Chabbert (1980)
Royston C. Clowes (1979)
C. Glenn Cobbs (1980)
Paul S. Cohen (1980)
Naomi Datta (1981)
Julian Davies (1979)
Lawrence E. Day (1980)
R. Gordon Douglas, Jr. (1980)
Theodore Eickhoff (1979)
Arthur English (1980)
David S. Feingold (1981)
Robert Fekety (1981)
Robert J. Fitzgerald (1980)
Anthony J. Glazko (1981)
Irving H. Goldberg (1979)
Harry Gooder (1979)
Jack Gwaltney (1980)
Fred Hahn (1979)
Robert L. Hamill (1979)
Maurice W. Harmon (1981)
Michael Higgins (1980)
Ronald D. Hinsdill (1979)
Richard Hornick (1980)

L. H. Huang (1979)
Milton Huppert (1980)
George Gee Jackson (1980)
Thomas Jones (1980)
William J. Jusko (1980)
Donald Kaye (1979)
Jerome O. Klein (1979)
Vernon Knight (1980)
George S. Kobayashi (1979)
Jordan Konisky (1980)
Matthew E. Levison (1981)
Friedrich C. Luft (1981)
Joan Lusk (1980)
R. Luthy (1980)
Gerald L. Mandell (1980)
Gerald Medoff (1980)
L. Bruce Mellett (1979)
S. Mitsunashi (1980)
Robert C. Moellering, Jr. (1979)
R. B. Morin (1979)
Bernard Moss (1981)
John D. Nelson (1980)
Harold C. Neu (1980)
J. F. Niblack (1980)
T. J. Perun (1980)
Charles A. Plate (1979)
Burton M. Pogell (1981)
K. E. Price (1979)
Paul Quie (1980)
W. H. G. Richards (1980)
Mark H. Richmond (1979)

R. W. Rickards (1980)
Richard Roberts (1979)
Richard Root (1980)
Jon E. Rosenblatt (1979)
Milton R. J. Salton (1981)
Merle Sande (1979)
Jay Sanford (1980)
Arthur K. Saz (1979)
F. C. Sciaolino (1979)
Oldrich K. Sebek (1980)
William M. Shannon (1980)
John C. Sherris (1979)
Charles Shipman, Jr. (1979)
Robert W. Sidwell (1981)
Walter Siegenthaler (1980)
Sigmund S. Socransky (1980)
P. Frederick Sparling (1981)
R. Sutherland (1979)
Vera L. Sutter (1981)
Morton N. Swartz (1979)
Clyde Thornberry (1979)
Ralph Tompsett (1979)
Hamao Umezawa (1981)
Donald Van Harken (1979)
D. Vazquez (1980)
Michael Waring (1981)
John Washington II (1981)
Jerry A. Weisbach (1979)
B. Weisblum (1979)
Peter G. Welling (1979)
Richard Wenzel (1980)

Robert A. Day, *Managing Editor*
Isella Pollock, *Assistant Managing Editor*
Lorraine Gilbert, *Production Editor*
1913 I St., NW, Washington, DC 20006

EX OFFICIO

Willis A. Wood, *President* (1979-1980)
J. Mehnen Joseph, *Secretary*

Albert Balows, *President-Elect* (1979-1980)
Brinton M. Miller, *Treasurer*

Antimicrobial Agents and Chemotherapy (ISSN 0066-4804), an interdisciplinary publication of the American Society for Microbiology, 1913 I St., N.W., Washington, D.C. 20006, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial agents and chemotherapy, including cancer chemotherapy. Instructions to Authors are published in the January issue each year. *Antimicrobial Agents and Chemotherapy* is published monthly, and the twelve numbers are divided into two volumes per year. The nonmember subscription price is \$65 per year. The member subscription price is \$16 per year. Single copies are \$6. Correspondence relating to subscriptions, reprints, defective copies, availability of back issues, lost or late proofs, disposition of submitted manuscripts, and general editorial matters should be directed to the ASM Publications Office, 1913 I St., NW, Washington, DC 20006 (area 202 833-9680).

日本：価格外貨表示とは関係なく円建。

Second class postage paid at Washington, D.C. 20006, and at additional mailing offices.

Made in the United States of America.

Copyright © 1979, American Society for Microbiology.

All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use, or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc., P.O. Box 765, Schenectady, New York 12301, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

- Bactericidal and Bacteriostatic Action of Chloramphenicol Against Meningeal Pathogens. JAMES J. RAHAL, JR.,* AND MICHAEL S. SIMBERKOFF 13
- Isolation and Properties of Metronidazole-Resistant Mutants of *Bacteroides fragilis*. M. L. BRITZ AND R. G. WILKINSON* 19
- Human Fibroblast Interferon for Clinical Trials: Production, Partial Purification, and Characterization. ALFONS BILLIAU,* JO VAN DAMME, FRED VAN LEUVEN, VICTOR G. EDY, MARC DE LEY, JEAN-JACQUES CASSIMAN, HERMAN VAN DEN BERGHE, AND PIET DE SOMER 49
- Mode of Action of the Azasteroid Antibiotic 15-Aza-24-Methylene-D-Homocholesta-8,14-Dien-3 β ol in *Ustilago maydis*. CHARLES P. WOLOSHUK,* HUGH D. SISLER, AND SAMSON R. DUTKY 81

Physiological Effects and Microbial Susceptibility

- Effects of Dextranases on Attachment of *Streptococcus mutans* to Hydroxyapatite. L. G. SIMONSON* AND D. JACKOLA 9
- In Vitro Synthesis of Peptidoglycan by β -Lactam-Sensitive and -Resistant Strains of *Neisseria gonorrhoeae*: Effects of β -Lactam and Other Antibiotics. CHRISTINE A. BROWN AND HAROLD R. PERKINS* 28
- Susceptibility of *Campylobacter fetus* subsp. *jejuni* to Twenty Antimicrobial Agents. MATS WALDER 37
- Comparison of a Micromethod for Performance of the Serum Bactericidal Test with the Standard Tube Dilution Method. CHARLES G. PROBER, SUSAN S. DOUGHERTY, KENNETH L. VOSTI,* AND ANNE S. YEAGER 46
- Antibacterial Activity of a New Parenteral Cephalosporin—HR 756: Comparison with Cefamandole and Ceforanide. GEORGE W. COUNTS* AND MARVIN TURCK 64
- In Vitro Comparison of Rosamicin and Erythromycin Against Urinary Tract Pathogens. THEODORE C. EICKHOFF* AND JOSEPHINE M. EHRET 69
- Morphological Changes of *Escherichia coli* Induced by Bicyclomycin. AKIRA SOMIYA, KENJI TANAKA, AND NOBUO TANAKA* 87
- Effect of 5-Iodo-2'-Amino-2',5'-Dideoxyuridine on Varicella-Zoster Virus In Vitro. JEFFREY P. ILTIS, TAI-SHUN LIN, WILLIAM H. PRUSOFF, AND FRED RAPP* 92
- Effects of Fildes Enrichment on Antibiotic Susceptibility Testing of *Haemophilus influenzae* in the Autobac. DAVID B. ROBINSON, RONALD F. SCHELL,* JACK L. LEFROCK, AND JOHN K. CHAN 98
- Inhibition of Cilia Regeneration of *Tetrahymena* by Ansamitocins, New Antitumor Antibiotics. SEIICHI TANIDA,* EIJI HIGASHIDE, AND MASAHICO YONEDA 101
- Isoniazid Inhibition of the Synthesis of Monounsaturated Long-Chain Fatty Acids in *Mycobacterium tuberculosis* H37Ra. LESLIE A. DAVIDSON AND KUNI TAKAYAMA* 104
- In Vitro Susceptibility of *Ureaplasma urealyticum* to Rosaramicin. THOMAS F. SMITH 106
- In Vitro Activity of Cefotaxime Against Cephalothin-Resistant Clinical Isolates. H. W. VAN LANDUYT* AND M. PYCKAVET 109
- Comparative In Vitro Activity of Five Cephalosporins Against Lactobacilli. ARNOLD S. BAYER,* ANTHONY W. CHOW, NELYDIA F. CONCEPCION, AND LUCIEN B. GUZE 112

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.

CONTENTS

Pharmacology and Therapeutics

Comparative Pharmacokinetics of Cephalexin, Cefaclor, Cefadroxil, and CGP 9000. HARTMUT LODE,* RALF STAHLMANN, AND PETER KOEPPE	1
Ventricular Fluid Levels of Chloramphenicol in Infants. RAM YOGEV* AND TOMMY WILLIAMS	7
Rapid, Simple Enzyme Immunoassay for Gentamicin. P. J. WILLS AND R. WISE*	40
Chloramphenicol Bioassay. ROBERT M. BANNATYNE* AND ROSE CHEUNG	43
Human Fibroblast Interferon for Clinical Trials: Pharmacokinetics and Tolerability in Experimental Animals and Humans. ALFONS BILLIAU,* PIET DE SOMER, VICTOR G. EDY, ERIK DE CLERCQ, AND HUBERTINE HEREMANS	56
Pharmacokinetics of Cephadrine Suspension In Infants and Children. CHARLES M. GINSBURG* AND GEORGE H. MCCrackEN, JR.	74
In Vitro Model Simulating the Form of Exposure of Bacteria to Antimicrobial Drugs Encountered in Infection. MOHAMMAD J. S. AL-ASADI, DAVID GREENWOOD,* AND FRANCIS O'GRADY	77

Volume 16

Contents for August

Number 2

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

In Vitro Antiherpesviral Activity of 5-Alkyl Derivatives of 1- β -D-Arabinofuranosyluracil. HARUHIKO MACHIDA,* SHINJI SAKATA, AKIRA KUNINAKA, HIROSHI YOSHINO, CHIKAO NAKAYAMA, AND MINEO SANEYOSHI	158
Streptomycin Resistance in a Streptomycin-Producing Microorganism. JANET M. PIWOWARSKI AND PAUL D. SHAW*	176
New Rapid Assay for Nafcillin in Serum by Spectrofluorometry. DIANE M. LICHTENWALNER, BYUNGSE SUH,* BENNETT LORBER, AND ALAN M. SUGAR	210
Spectrophotometric Assay for Amikacin, Using Purified Kanamycin Acetyltransferase. EMANUEL SCARBROUGH, JEFFREY W. WILLIAMS, AND DEXTER B. NORTROP*	221
Inhibition by Ethambutol of Mycolic Acid Transfer into the Cell Wall of <i>Mycobacterium smegmatis</i> . KUNI TAKAYAMA,* EMMA L. ARMSTRONG, KEITH A. KUNUGI, AND JAMES O. KILBURN	240

Physiological Effects and Microbial Susceptibility

Comparison of the Activities of the New Ureidopenicillins Piperacillin, Mezlocillin, Azlocillin, and Bay k 4999 Against Gram-Negative Organisms. LUDO VERBIST	115
In Vitro Activity of Sodium Fusidate Against Anaerobic Bacteria. G. E. STEINKRAUS AND L. R. MCCARTHY*	120
Oxacillin-Induced Lysis of <i>Staphylococcus aureus</i> . ROBERT H. RAYNOR, DAVID F. SCOTT, AND GARY K. BEST*	134
Antibacterial Activity of a New 1-Oxa Cephalosporin Compared with That of Other β -Lactam Compounds. HAROLD C. NEU,* NALINEE ASWAPOKEE, KWUNG P. FU, AND PRASIT ASWAPOKEE	141
Comparative Activity and β -Lactamase Stability of Cefoperazone, a Piperazine Cephalosporin. HAROLD C. NEU,* KWUNG P. FU, NALINEE ASWAPOKEE, PRASIT ASWAPOKEE, AND KET KUNG	150
Diffusion Disk Susceptibility Testing with Cefotaxime. NALINEE ASWAPOKEE, PRASIT ASWAPOKEE, HAROLD C. NEU,* AND KWUNG P. FU	164
Antibiotic Susceptibility of <i>Haemophilus vaginalis</i> (<i>Corynebacterium vaginale</i>) to	

CONTENTS

21 Antibiotics. LAURENCE R. MCCARTHY,* PATRICIA A. MICKELSEN, AND E. GROVER SMITH	186
Antimicrobial Susceptibility Testing of Pneumococci: Determination of Kirby-Bauer Breakpoints for Penicillin G, Erythromycin, Clindamycin, Tetracycline, Chloramphenicol, and Rifampin. M. R. JACOBS,* Y. MITHAL, R. M. ROBINS-BROWNE, M. N. GASPAR, AND H. J. KOORNHOF	190
Importance of Medium in Demonstrating Penicillin Tolerance by Group B Streptococci. KWANG SIK KIM, ROBERT N. YOSHIMORI, DAVID T. IMAGAWA, AND BASCOM F. ANTHONY*	214
In Vitro Susceptibilities of <i>Naegleria fowleri</i> Strain HB-1 to Selected Antimicrobial Agents, Singly and in Combination. KENNETH K. LEE, STEPHEN L. KARR, JR.,* MING M. WONG, AND PAUL D. HOEPRICH	217
Decrease of Drug Resistance in <i>Salmonella</i> in The Netherlands. W. J. VAN LEEUWEN, J. VAN EMBDEN, P. GUINÉE,* E. H. KAMPELMACHER, A. MANTEN, M. VAN SCHOTHORST, AND C. E. VOOGD	237
Activity of β -Lactam Antibiotics Against <i>Pseudomonas aeruginosa</i> Carrying R Plasmids Determining Different β -Lactamases. GEORGE A. JACOBY* AND LORRAINE SUTTON	243

Pharmacology and Therapeutics

Development of Resistance to Amphotericin B in <i>Candida lusitanae</i> Infecting a Human. D. PAPPAGIANIS,* M. S. COLLINS, R. HECTOR, AND J. REMINGTON ..	123
Human Pharmacology of Cefotaxime (HR 756), a New Cephalosporin. RUEDI LÜTHY,* REINER MÜNCH, JÜRGE BLASER, HANSJÖRG BHEND, AND WALTER SIEGENTHALER	127
Etiology of Tetracycline-Associated Pseudomembranous Colitis in Hamsters. RENU TOSHNIWAL, ROBERT FEKETY,* AND JOSPEH SILVA, JR.	167
Treatment of Bacterial Meningitis with Intravenous Amoxicillin. CHARLES M. NOLAN,* ELIAS G. CHALHUB, DONNA G. NASH, AND TERRY YAMAUCHI	171
Clinical and Bacteriological Evaluation of Cefoxitin Therapy in Children. JAY A. JACOBSON,* JOSE I. SANTOS, AND W. MARTIN PALMER	183
Ampicillin Dosage in Bacterial Meningitis with Special Reference to <i>Haemophilus influenzae</i> . G. R. GREENE, G. D. OVERTURE,* AND P. F. WEHRLE	198
Effects of Amphotericin B and Its Methyl Ester on the Antiviral Activity of Polyinosinic:Polycytidylic Acid. ERNEST C. BORDEN,* JACK A. MCBAIN, AND PEGGY H. LEONHARDT	203
Persistence of Plasmid-Carrying Tetracycline-Resistant <i>Escherichia coli</i> in a Married Couple, One of Whom Was Receiving Antibiotics. V. PETROCHEILOU, M. H. RICHMOND,* AND P. M. BENNETT	225
Renal Transport of Organic Acids and Bases in Aminoglycoside Nephrotoxicity. WILLIAM M. BENNETT,* CHARLES E. PLAMP, RICHARD A. PARKER, DAVID N. GILBERT, DONALD C. HOUGHTON, AND GEORGE A. PORTER	231
Pharmacokinetics of E-5-(2-Bromovinyl)-2'-Deoxyuridine in Mice. E. DE CLERCQ,* J. DESCAMPS, P. DE SOMER, P. J. BARR, A. S. JONES, AND R. T. WALKER ...	234

Errata

Inhibition of <i>Escherichia coli</i> K-12 by β -Lactam Antibiotics With Poor Antibacterial Activity: Interaction of Permeability and Intrinsic Activity Against Penicillin-Binding Proteins. NIGEL A. C. CURTIS, CAROL BROWN, MIKE BOX-ALL, AND MICHAEL G. BOULTON	246
Penetrability of the Outer Membrane of <i>Neisseria gonorrhoeae</i> in Relation to Acquired Resistance to Penicillin and Other Antibiotics. R. ALLAN SCUDAMORE, TERRANCE J. BEVERIDGE, AND MORRIS GOLDNER	246

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

- Enhancement of Post-Ultraviolet Killing in *Escherichia coli* K-12 Through the Action of Gyrase Inhibitors: Evidence for Associated Gyrase-*recBC* Deoxyribonuclease Function. MICHAEL A. PURDY* AND K. LEMONE YIELDING 247
- Aflatoxin Inhibition of Viral Interferon Induction. NICHOLAS HAHON,* JAMES A. BOOTH, AND JOHN D. STEWART 277
- Purification and Characterization of Agrocin 84. R. J. THOMPSON, R. H. HAMILTON, AND CHRISTINE F. POOTJES* 293
- High-Pressure Liquid Chromatography Analysis of Antibiotic Susceptibility Disks. ROBERT B. HAGEL, EDWARD H. WAYSEK, AND WINIFRED M. CORT* 372
- Piperacillin Susceptibility Tests by the Single-Disk Agar Diffusion Technique. A. L. BARRY,* C. THORNSBERRY, R. E. BADAL, C. N. BAKER, R. N. JONES, AND C. H. GERLACH 378
- Isolation and Nature of Intracellular Alpha-Aminoadipic Acid-Containing Peptides from *Paecilomyces persicinus* P-10. LOUIS A. ERIQUEZ* AND MICHAEL A. PISANO 392
- Use of Covalently Closed Circular Deoxyribonucleic Acid for Prescreening for Antitumor Compounds. SEYMOUR MONG,* JAMES E. STRONG, JAMES A. BUSH, AND STANLEY T. CROOKE 398

Physiological Effects and Microbial Susceptibility

- Australian Evaluation of Autobac I with Suggested Interpretive and Technical Modifications. GLENN R. FUNNELL* AND MICHAEL D. G. GUINNESS 255
- Sanguicin, a Bacteriocin of Oral *Streptococcus sanguis*. SETSUO FUJIMURA* AND TAKESHI NAKAMURA 262
- Activity of Semisynthetic Penicillins and Synergism with Mecillinam Against *Bacteroides* Species. IRWIN TRESTMAN, DONALD KAYE, AND MATTHEW E. LEVISON* 283
- In Vitro Activity of LY127935. MICHAEL BARZA,* FRANCIS P. TALLY, NILDA V. JACOBUS, AND SHERWOOD L. GORBACH 287
- LY-127935: a Novel Beta-Lactam Antibiotic with Unusual Antibacterial Activity. GARY M. TRAGER,* G. WESLEY WHITE, VICTORIA M. ZIMELIS, AND ANAND P. PANWALKER 297
- RMI 15,731 (1-[5-Tetradecyloxy-2-furanyl]-ethanone), a New Antirhinovirus Compound. RONALD J. ASH,* ROGER A. PARKER, ANNE C. HAGAN, AND GERALD D. MAYER 301
- Antibiotic Susceptibilities of Human Isolates of *Pasteurella multocida*. DENNIS L. STEVENS,* JAMES W. HIGBEE, THOMAS R. OBERHOFER, AND E. DALE EVERETT 322
- Competition of β -Lactam Antibiotics for the Penicillin-Binding Proteins of *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Klebsiella aerogenes*, *Proteus rettgeri*, and *Escherichia coli*: Comparison with Antibacterial Activity and Effects upon Bacterial Morphology. NIGEL A. C. CURTIS,* DAVID ORR, GORDON W. ROSS, AND MICHAEL G. BOULTON 325
- N^o-Cocoyl L-Arginine Ethyl Ester, DL-Pyroglutamic Acid Salt, As an Inactivator of Hepatitis B Surface Antigen. YOSHIKAZU SUGIMOTO* AND SHIGESHI TOYOSHIMA 329
- Comparison of the Penicillin-Binding Proteins of Different Strains of *Neisseria gonorrhoeae*. R. D. NOLAN* AND J. F. HILDEBRANDT 336
- LY127935, a Novel Oxa- β -Lactam: An In Vitro Comparison with Other β -Lactam Antibiotics. R. WISE,* J. M. ANDREWS, AND K. A. BEDFORD 341

CONTENTS

Lytic Effect of Di- or Tricarboxylic Acids Plus Sodium Dodecyl Sulfate Against <i>Pseudomonas aeruginosa</i> . FRANK W. ADAIR,* SAM G. GEFTIC, AND HANS HEYMANN	417
Virucidal Activity of Retinal. ALBERT REINHARDT, JEFFREY A. SANDS,* AND WALLACE SNIPES	421
Comparison of Cefamandole Nafate to Cefamandole by Microbiological Assay. CARL L. WINELY,* JOSEPH C. SPEARS, AND JACK K. SCOTT	424
Pharmacology and Therapeutics	
Experimental Endocarditis: Prophylaxis of <i>Candida albicans</i> Infections by 5-Fluorocytosine in Rabbits. GEORGES DEMIERRE AND LAWRENCE R. FREEDMAN*	252
Latent Infections of Sensory Ganglia as Influenced by Phosphonoformate Treatment of Herpes Simplex Virus-Induced Skin Infections in Hairless Mice. RICHARD J. KLEIN,* EUGENE DE STEFANO, EILEEN BRADY, AND ALVIN E. FRIEDMAN-KIEN	266
Mecillinam-Ampicillin Synergism in Experimental <i>Enterobacteriaceae</i> Meningitis. W. M. SCHELD, F. N. FINK, D. D. FLETCHER, AND M. A. SANDE*	271
Phosphonopeptides as Antibacterial Agents: Metabolism and Pharmacokinetics of Alafosfalin in Animals and Humans. JOHN G. ALLEN,* LADISLAUS HAVAS, ERNST LEICHT, IAN LENOX-SMITH, AND LOUIS J. NISBET	306
Antibiotic Activity In Vitro Against Methicillin-Resistant <i>Staphylococcus epidermidis</i> and Therapy of an Experimental Infection. FRANKLIN D. LOWY, JULIA A. WALSH, MARGUERITE M. MAYERS, ROBERT S. KLEIN, AND NEAL H. STEIGBIGEL*	314
Limited Effect of Trimethoprim-Sulfamethoxazole Prophylaxis on <i>Pneumocystis carinii</i> . WALTER T. HUGHES	333
Clinicopharmacological Evaluation of Amoxicillin and Probenecid Against Bacterial Meningitis. J. CARL CRAFT, WILLIAM E. FELDMAN, AND JOHN D. NELSON*	346
Correlation of Aminoglycoside Dosages with Serum Concentrations During Therapy of Serious Gram-Negative Bacillary Disease. MICHAEL T. REYMAN,* JAMES A. BRADAC, C. GLENN COBBS, AND WILLIAM E. DISMUKES	353
Cochlear Toxicity of Butikacin (UK-18,892), a New Semisynthetic Aminoglycoside Antibiotic, in Guinea Pigs. ANTHONY J. CARTER	362
Anaerobic Infection in Cancer Patients: Comparative Evaluation of Clindamycin and Cefoxitin. J. KLASTERSKY,* L. COPPENS, AND G. MOMBELLI	366
Ceforanide: In Vitro and Clinical Evaluation. KEITH H. BURCH,* DONALD POHLOD, LOUIS D. SARAVOLATZ, TOM MADHAVAN, DARIA KIANI, EDWARD L. QUINN, RAMON DEL BUSTO, JULIO CARDENAS, AND EVELYN J. FISHER	386
Netilmicin Treatment of Complicated Urinary Tract Infection in Patients with Renal Function Impairment. N. FRIMODT-MÖLLER, S. MAIGAARD, AND P. O. MADSEN*	406
Cinoxacin: Pharmacokinetics and Tolerance in Patients with Normal and Impaired Renal Function. SVEND MAIGAARD, NIELS FRIMODT-MÖLLER, PETER G. WELLING, AND PAUL O. MADSEN*	411

Volume 16

Contents for October

Number 4

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

β -Lactam Resistance in Clinical Isolates of <i>Escherichia coli</i> Caused by Elevated Production of the <i>ampC</i> -Mediated Chromosomal β -Lactamase. SVEN BERGSTRÖM* AND STAFFAN NORMARK	427
---	-----

CONTENTS

- Mechanism of Synergistic Action of a Combination of Ampicillin and Dicloxacillin Against a β -Lactamase-Producing Strain of *Citrobacter freundii*. JUNZO MIZOGUCHI, HIDEKAZU SUGINAKA,* AND SHOZO KOTANI 439

Physiological Effects and Microbial Susceptibility

- Effect of Divalent Cation Concentrations on the Antibiotic Susceptibilities of Nonfermenters Other than *Pseudomonas aeruginosa*. ROBERT J. FASS* AND JEAN BARNISHAN 434
- Alafosfalin, a New Inhibitor of Cell Wall Biosynthesis: In Vitro Activity Against Urinary Isolates in Japan and Potentiation with β -Lactams. HIROMI B. MARUYAMA,* MIKIO ARISAWA, AND TOYOAKI SAWADA 444
- Agar Medium for Use in Susceptibility Testing of Bacteria From Human Periodontal Pockets. CLAY B. WALKER,* THEODORE A. NIEBLOOM, AND SIGMUND S. SOCRANSKY 452
- In Vitro Response of *Enterobacter* to Ampicillin. MARY F. LAMPE, BARBARA H. MINSHEW, AND JOHN C. SHERRIS* 458
- Assay of Serum Tobramycin Levels with the Bactec 460. L. E. PHILLIPS,* ROBERT R. MARTIN, LAYNE O. GENTRY, AND T. E. ROGERS 463
- Lipid Composition and Sensitivity of *Prototheca wickerhamii* to Membrane-Active Antimicrobial Agents.INDER JIT SUD AND DAVID S. FEINGOLD* 486
- Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria. VERA L. SUTTER,* ARTHUR L. BARRY, TRACY D. WILKINS, AND RONALD J. ZABRANSKY 495
- In Vitro Activity of LY127935. ROBERT J. FASS 503
- Effect of Inoculum Size on the Susceptibility of *Haemophilus influenzae* b to Beta-Lactam Antibiotics. V. PH. SYRIOPOULOU, D. W. SCHEIFELE, C. M. SACK, AND A. L. SMITH* 510
- In Vitro Antimicrobial Inhibition Patterns of Nutritionally Variant Streptococci. ROBERT C. COOKSEY* AND JANA M. SWENSON 514
- Antimicrobial Susceptibility of Clinical Isolates of *Serratia marcescens*. J. S. ALVAREZ,* B. REGUEIRO, AND M. J. GARRIDO 523
- Erythromycin and Clindamycin Resistance in *Corynebacterium diphtheriae* from Skin Lesions. MARIE B. COYLE,* BARBARA H. MINSHEW, JUDITH A. BLAND, AND PATRICIA C. HSU 525

Pharmacology and Therapeutics

- Urinary Casts as an Indicator of Renal Tubular Damage in Patients. JEROME J. SCHENTAG,* FRANCIS M. GENGO, MARTIN E. PLAUT, DAVID DANNER, ANTOINETTE MANGIONE, AND WILLIAM J. JUSKO 468
- Antimalarial Properties of Floxacrine, a Dihydroacridinedione Derivative. L. H. SCHMIDT 475
- Comparative Nephrotoxicity of SCH 21420 and Amikacin in Rats. L. I. RANKIN,* F. C. LUFT, M. N. YUM, R. S. SLOAN, C. B. DINWIDDIE, JR., AND L. L. ISAACS 491
- Oral Neomycin Dosage Schedules for Suppression of Ammonia Production by Bowel Flora. BYUNGSE SUH, JAMES L. STEPHENS, AND CALVIN M. KUNIN* 519

Erratum

- Antibacterial Activity of a New 1-Oxa Cephalosporin Compared with That of Other β -Lactam Compounds. HAROLD C. NEU, NALINEE ASWAPOKEE, KWUNG P. FU, AND PRASIT ASWAPOKEE 528

CONTENTS

Volume 16

Contents for November

Number 5

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

- Assay of Flucytosine (5-Fluorocytosine) in Human Plasma by High-Pressure Liquid Chromatography. ROSS W. BURY,* MAURICE L. MASHFORD, AND HELEN M. MILES 529
- Affinities of Penicillins and Cephalosporins for the Penicillin-Binding Proteins of *Escherichia coli* K-12 and Their Antibacterial Activity. NIGEL A. C. CURTIS,* DAVID ORR, GORDON W. ROSS, AND MICHAEL G. BOULTON 533
- Inactivation of β -LACTAM Antibiotics by *Legionella pneumophila*. KWUNG P. FU AND HAROLD C. NEU* 561
- Inactivation of Cephalosporin by *Bacteroides*. FRANCIS P. TALLY,* J. PAUL O'KEEFE, N. M. SULLIVAN, AND SHERWOOD L. GORBACH 565
- Biosynthetic Pathway Leading to Gentamicin C_{2b}. B. K. LEE,* T. L. NAGABHUSHAN, R. G. CONDON, G. SHIMONASKI, M. G. KALYANPUR, M. PATEL, AND J. A. WAITZ 589
- Amikacin Resistance Associated with a Plasmid-Borne Aminoglycoside Phosphotransferase in *Escherichia coli*. MICHAEL H. PERLIN AND STEPHEN A. LERNER* 598
- Effect of Free Fatty Acids on Liposome Susceptibility to Imidazole Antifungals. Inder J. Sud, Dong-Lang Chou, and David S. Feingold* 660
- High-Level, Plasmid-Borne Resistance to Gentamicin in *Streptococcus faecalis* subsp. *zymogenes*. THEA HORODNICEANU,* LYDIE BOUGUELERET, NÉVINE EL-SOLH, GILDA BIETH, AND FRANÇOISE DELBOS 686

Physiological Effects and Microbial Susceptibility

- Antibacterial Activity of Ceftizoxime (FK 749), a New Cephalosporin, Against Cephalosporin-Resistant Bacteria, and Its Stability to β -Lactamase. HITOSHI KOJO, MINORU NISHIDA,* SACHIKO GOTO, AND SHOGO KUWAHARA 549
- Antibiotics and Suppression of Lymphocyte Function in Vitro. GÖRAN BANCK* AND ARNE FORSGREN 554
- Rapid Assay for Determination of Trimethoprim and Sulfamethoxazole Levels in Serum by Spectrofluorometry. DIANE M. LICHTENWALNER, BYUNGSE SUH,* BENNETT LORBER, AND ALAN M. SUGAR 579
- Disk Diffusion Testing of Susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonae* to Antibacterial Agents. RICHARD J. WALLACE, JR.,* JOSEPH R. DALOVISIO, AND GEORGE A. PANKEY 611
- Minimal Inhibitory Concentrations of 34 Antimicrobial Agents for Control Strains *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853. ROBERT J. FASS* AND JEAN BARNISHAN 622
- Agar Disk Diffusion Susceptibility Characteristics of Azlocillin, Carbenicillin, Mezlocillin, Piperacillin, and Ticarcillin. DENIS PHANEUF AND HAROLD C. NEU* 625
- Evaluation of the Bactec Serum Gentamicin Assay. JOHN P. MANOS* AND PATRICIA F. JACOBS 631
- LY127935, a New Beta-Lactam Antibiotic, Versus *Proteus*, *Klebsiella*, *Serratia*, and *Pseudomonas*. D. J. FLOURNOY* AND FRED A. PERRYMAN 641
- Susceptibility and Synergy Studies of Methicillin-Resistant *Staphylococcus epidermidis*. MICHAEL E. EIN, NEDRA J. SMITH, JOHN F. ARUFFO, MARK S. HEEREMA, MAJOR W. BRADSHAW, AND TEMPLE W. WILLIAMS, JR.* 655
- Variability in the Susceptibility Pattern of *Bacteroides fragilis* in Four Detroit Area Hospitals. ROGER E. BAWDON,* ELZBIETA ROZMIEJ, SUNIL PALCHAU-DHURI, AND JANET KRAKOWIAK 644

CONTENTS

In Vitro Activity of Three Tetracycline Antibiotics Against <i>Acinetobacter calcoaceticus</i> subsp. <i>anitratus</i> . JOHN V. CRUES III, BARBARA E. MURRAY, AND ROBERT C. MOELLERING, JR.*	690
Pharmacology and Therapeutics	
Ceftizoxime (FK 749), a New Parenteral Cephalosporin: In Vitro and In Vivo Antibacterial Activities. TOSHIAKI KAMIMURA, YOSHIMI MATSUMOTO, NAOHIKO OKADA, YASUHIRO MINE, MINORU NISHIDA,* SACHIKO GOTO, AND SHOGO KUWAHARA	540
Amantadine Aerosol in Humans. VERNON KNIGHT,* KIM BLOOM, SAMUEL Z. WILSON, AND R. KEITH WILSON	572
Pharmacokinetics of Cefamandole and Ampicillin in Experimental Meningitis. HARRY N. BEATY* AND ELWANDA WALTERS	584
Pharmacokinetics of Cefotaxime. KWUNG P. FU, PRASIT ASWAPOKEE, IRWIN HO, CHARLES MATTHIJSSEN, AND HAROLD C. NEU*	592
Clinical Evaluation of Mezlocillin. H. THADEPALLI* AND BHAVANI RAO	605
Clinical Pharmacokinetics and Safety of High Doses of Ceforanide (BL-S786R) and Cefazolin. ROBERT D. SMYTH,* MORRIS PFEFFER, AARON GLICK, DONALD R. VAN HARKEN, AND GIRARD H. HOTTENDORF	615
Ineffectiveness of Erythromycin for Treatment of <i>Haemophilus vaginalis</i> -Associated Vaginitis: Possible Relationship to Acidity of Vaginal Secretions. MARCIA A. DURFEE, PATRICIA S. FORSYTH, JUDITH A. HALE, AND KING K. HOLMES*	635
Induction and Prevention of Experimental Arteriovenous Fistula Infections. TIMOTHY W. LANE* AND ELIAS ABRUTYN	638
Amantadine Aerosols in Normal Volunteers: Pharmacology and Safety Testing. FREDERICK G. HAYDEN,* WILLIAM J. HALL, R. GORDON DOUGLAS, JR., AND DONNA M. SPEERS	644
Mezlocillin Pharmacokinetics in Patients with Normal and Impaired Renal Functions. T. BERGAN,* E. K. BRODWALL, AND E. WIIK-LARSEN	651
Effect of Azacytidine on Simian Virus 40 Nucleoprotein Complexes. MARIAN JOHNSON-THOMPSON AND LEONARD J. ROSENTHAL*	667
Susceptibility of <i>Naegleria fowleri</i> to Δ^9 -Tetrahydrocannabinol. H. L. PRINGLE, S. G. BRADLEY,* AND L. S. HARRIS	674
Relative Potencies of Different Anti-Herpes Agents in the Topical Treatment of Cutaneous Herpes Simplex Virus Infection of Athymic Nude Mice. J. DESCAMPS, E. DE CLERCQ,* P. J. BARR, A. S. JONES, R. T. WALKER, P. F. TORRENCE, AND D. SHUGAR	680
Hydrolysis of Cefamandole Nafate in Dialysis Patients. RICHARD L. NIELSEN, ROBERT WOLEN, FRIEDRICH C. LUFT,* AND TAKESHI OZAWA	683
Errata	
Comparative Pharmacokinetics of Cephalexin, Cefaclor, Cefadroxil, and CGP 9000. HARTMUT LODE, RALF STAHLMAN, AND PETER KOEPPE	693
Antimicrobial Susceptibility Testing of Pneumococci: Determination of Kirby-Bauer Breakpoints for Penicillin G, Erythromycin, Clindamycin, Tetracycline, Chloramphenicol, and Rifampin. M. R. JACOBS, Y. MITHAL, R. M. ROBINS-BROWNE, M. N. GASPAR, AND H. J. KOORNHOF	693

Volume 16

Contents for December

Number 6

Biosynthesis; Chemistry; Mechanisms of Action and Resistance

Kinetic Studies on Enzymatic Acetylation of Chloramphenicol in <i>Streptococcus faecalis</i> . YOJI NAKAGAWA, YOSHIYUKI NITAHARA, AND SADA O MIYAMURA*	719
--	-----

CONTENTS

Characterization and Mode of Action of a Bacteriocin Produced by a <i>Bacteroides fragilis</i> Strain. KEVIN G. MOSSIE, DAVID T. JONES, FRANK T. ROBB, AND DAVID R. WOODS*	724
Compounds Affecting Membranes That Inhibit Protein Synthesis in Yeast. M. A. ALONSO, D. VÁZQUEZ, AND L. CARRASCO*	750
Increased Production of Beta-Lactamase Under Anaerobic Conditions in Some Strains of <i>Escherichia coli</i> . AYOUN RASHTCHIAN, ROYA NOURAVARSANI, G. R. MILLER,* AND E. H. GERLACH	772
Microbial Transformation of A23187, a Divalent Cation Ionophore Antibiotic. BERNARD J. ABBOT,* DAVID S. FUKUDA, DOUGLAS E. DORMAN, JOHN L. OCCOLOWITZ, MANUEL DEBONO, AND LESTER FARHNER	808
Triggering of Autolytic Cell Wall Degradation in <i>Escherichia coli</i> by Beta-Lactam Antibiotics. KAZUAKI KITANO AND ALEXANDER TOMASZ*	838
Temperature-Sensitive 6-Aminopenicillanic Acid-Resistant Mutants of <i>Escherichia coli</i> . EDWARD E. ISHIGURO,* MAKOTO IWAYA, AND WILLIAM TURLEY	849
Effects of Cerulenin on Antibiotic-Induced Lysis of <i>Streptococcus faecalis</i> (<i>S. faecium</i>). L. DANE0-MOORE,* P. BOURBEAU, R. WEINSTEIN, AND D. CARSON	858
Physiological Effects and Microbial Susceptibility	
Enhancement of Leukocyte Activity Against <i>Escherichia coli</i> After Brief Exposure to Chloramphenicol. HENDRIK PRUUL* AND PETER J. McDONALD	695
Incidence of Antibiotic-Resistant <i>Escherichia coli</i> Associated with Frozen Chicken Carcasses and Characterization of Conjugative R Plasmids Derived from Such Strains. SUZANNE D. CAUDRY AND VILMA A. STANISICH*	701
Quantitative Assessment of Antimalarial Activity In Vitro by a Semiautomated Microdilution Technique. ROBERT E. DESJARDINS,* CRAIG J. CANFIELD, J. DAVID HAYNES, AND JEFFREY D. CHULAY	710
In Vitro Antibacterial Activity of Cefoperazone (T-1551), a New Semisynthetic Cephalosporin. N. MATSUBARA,* S. MINAMI, T. MURAOKA, I. SAIKAWA, AND S. MITSUHASHI	731
Rifampin Plus Trimethoprim: Bactericidal Activity and Suppression of Resistance in Human Urine In Vitro. BETH P. GOLDSTEIN,* I. FRANCA RIPAMONTI, GIULIANA BOLZONI, GIULIANA CARNITI, AND VITTORIO ARIOLI	736
Gentamicin Antibacterial Activity in the Presence of Human Polymorphonuclear Leukocytes. PIERRE VAUDAUX AND FRANCIS A. WALDVOGEL*	743
Comparison of Activity and Beta-Lactamase Stability of Cefotaxime with Those of Six Other Cephalosporins. R. PETER MOUTON,* GER P. A. BONGAERTS, AND MARIETTE VAN GESTEL	757
Bactericidal Effect of Combinations of Antimicrobial Drugs and Antineoplastic Antibiotics Against Gram-Negative Bacilli. JACQUES MICHEL, JOHN Y. JACOBS,* AND THEODORE SACKS	761
Phosphorylation of Streptozotocin During Uptake via the Phosphoenolpyruvate: Sugar Phosphotransferase System in <i>Escherichia coli</i> . JOHANNES AMMER, MARGARETE BRENNENSTUHL, PETER SCHINDLER, JOACHIM-VOLKER HÖLTJE,* AND HANS ZÄHNER	801
Fortimicin A: Collaborative In Vitro Susceptibility Comparison with Amikacin and Gentamicin Against 11,840 Clinical Bacterial Isolates. RONALD N. JONES,* ARTHUR L. BARRY, PETER C. FUCHS, THOMAS L. GAVAN, HERBERT M. SOMMERS, AND E. HUGH GERLACH	823
Susceptibility of <i>Pseudomonas maltophilia</i> to Antimicrobial Agents, Singly and in Combination. TERRANCE P. FELEGIE, VICTOR L. YU,* LARRY W. RUMANS AND ROBERT B. YEE	833
Chlorhexidine as an Effective Agent Against <i>Chlamydia trachomatis</i> In Vitro and	

CONTENTS

In Vivo. IAN T. NISBET,* DORIS M. GRAHAM, PAUL E. SPICER, AND G. JOHN TIBBS	855
In Vitro Activity of LY127935, a New 1-Oxa Cephalosporin, Against Aerobic Gram-Negative Bacilli. DENNIS G. DELGADO, CARMEN J. BRAU, C. GLENN COBBS, AND WILLIAM E. DISMUKES*	864
Pharmacology and Therapeutics	
Bronchial Secretion Levels of Amikacin. WILLIAM L. DULL, MICHAEL R. ALEXANDER, AND JOHN E. KASIK*	767
Rosaramicin Versus Penicillin G in Experimental Pneumococcal Meningitis. CHARLES M. NOLAN,* THOMAS P. MONSON, AND W. CLYDE ULMER, JR.	776
Effects of Interferon and Adenine Arabinoside Treatment of Hepatitis B Virus Infection on Cellular Immune Responses. BARRY HAFKIN, RICHARD B. POLLARD, MOTI L. TIKU, WILLIAM S. ROBINSON, AND THOMAS C. MERIGAN*	781
Pharmacokinetics of Intravenous Piperacillin Patients Undergoing Chronic Hemodialysis. ELLIOT L. FRANCKE, GERALD B. APPEL, AND HAROLD C. NEU*	788
Miconazole Therapy for Treatment of Fungal Infections in Cancer Patients. WILLIAM M. JORDAN, GERALD P. BODEY,* VICTORIA RODRIGUEZ, STEVEN J. KETCHEL, AND JANE HENNEY	792
Clavulanic Acid and Penicillin Treatment of <i>Staphylococcus aureus</i> Renal Infection in Mice. MARK S. HEEREMA, DANIEL M. MUSER,* AND TEMPLE W. WILLIAMS, JR.	798
Antibacterial Activities, Nephrotoxicity, and Ototoxicity of a New Aminoglycoside, Win 42122-2. PAUL E. CAME,* JOHN R. O'CONNOR, RICHARD A. DOBSON, ROLAND B. WAGNER, AND RAYMOND J. FABIAN	813
Amikacin Pharmacokinetics in Pediatric Patients with Malignancy. THOMAS G. CLEARY,* LARRY K. PICKERING, WILLIAM G. KRAMER, STEVE CULBERT, LAWRENCE S. FRANKEL, AND STEVE KOHL	829
Evaluation of Gentamicin and Penicillin as a Synergistic Combination in Experimental Murine Listeriosis. C. E. EDMISTON, JR., AND R. C. GORDON*	862
Effect of Cefamandole Nafate on Blood Coagulation and Platelet Function. GALEN M. CUSTER, BRUCE R. BRIGGS, AND ROY E. SMITH*	869
Erratum	
Competition of β -Lactam Antibiotics for the Penicillin-Binding Proteins of <i>Pseudomonas aeruginosa</i> , <i>Enterobacter cloacae</i> , <i>Klebsiella aerogenes</i> , <i>Proteus rettgeri</i> , and <i>Escherichia coli</i> : Comparison with Antibacterial Activity and Effects upon Bacterial Morphology. NIGEL A. C. CURTIS, DAVID ORR, GORDON W. ROSS, AND MICHAEL B. BOULTON	873

INDEX TO DATE OF ISSUE

Month	Date of Issue	Pages
July	12 July 1979	1-113
August	6 August 1979	115-246
September	20 September 1979	247-426
October	8 October 1979	427-528
November	26 November 1979	529-693
December	21 December 1979	695-873